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ABSTRACT
Three Shetland ponies (A, B and C) were inoculated with plasma from
a pony with clinical signs of equine infectious anemia (EIA) and observed
for

165 to 440 days.

Clinical signs of EIA marked by high fever

( 39.5°C) lasting 2-4 days were observed 2-3 weeks after infection and
one to four such episodes occurred in each pony.

EIAV was reisolated

from plasma by end-point dilution in fetal equine kidney (FEK) cells and
a plasma viremia

103-5 TCID50/m l was observed during each episode.

A

total of seven virus isolates were recovered.
Cross-neutralization tests with sequential serum samples showed that
the four viruses isolated from pony A during febrile episodes 4-5 weeks
apart were serologically different.
isolates

revealed additions

immediate

predecessor.

including

those

from

Tryptic peptide map analysis of these

or deletions between

.Western blot
ponies

B

and

each

analysis
C with

isolate

of these
a

panel

and

four

its

isolates

of monoclonal

antibodies confirmed antigenic variation in both gp90 and gp45.

Both

conserved and variable epitopes were identified in each glycoprotein with
greatest

variation in

gp90.

Analysis with

MAbs

confirmed

similar

antigenic variation in an in vitro variant generated in cell culture.
The

humoral response

to

EIAV was

monitored

for

anti-virus

antibodies by AGID, Western blots and a novel single-step immunoblot
devisedin this study for rapid

assay of EIAV antibodies and

antigens.

Specific IgG directed against determinants of EIAV gp90, gp45 and p26 in
homologous

and

heterologous virus isolates was detectable within one

month after infection.

The group-specific determinants in gp90 and gp45

were more antigenic than those in p26.

Neutralizing antibodies first

detectable within two months were observed to

be

effective

only to

viruses isolated prior to serum collection but became broadly reactive
later in the infection regardless of the number of clinical episodes.
Our

data

showed

that

rapid

persistent infection with EIAV

antigenic

in ponies

variation

and

occurred

during

in cell culture in the

presence of immune serum, and neutralizing antibody response broadened
during the course of EIA.

The conserved antigenic determinants of EIAV

gp90 and gp45 identified in this and previous studies will be useful in
diagnostic procedures and may have potential for vaccines against EIA.

CHAPTER ONE

LITERATURE REVIEW

EQUINE INFECTIOUS ANEMIA (EIA):

A LENTIVIRUS DISEASE OF

HORSES.
Equine infectious anemia (EIA) is a naturally occurring viral disease
of all

Equidae.The

characterized
marrow

by

disease

recurrent

depression,

has

a world-wide

episodes of fever,

lymphoproliferation,

a

life

distribution

hemolytic

anemia,

long persistent

and immunologically-mediated lesions (18, 29, 36, 68, 107).

and

is

bone

infection

The etiological

agent of EIA is an exogenous replication competent retrovirus that is
more closely related to the lentiviruses than to the other subfamilies of
retroviruses (15, 16, 56,

125, 133, 165).

The disease has a variable

clinical course; but in natural infections, the disease is mostly inapparent
(77).

The nature of EIA virus (EIAV) induced clinical signs, the presence

of immunologically mediated lesions and the relatedness of this equine
virus to both human and other animal lentiviruses make EIA a good model
for the elucidation of mechanisms involved in the persistence of viral
infections in immunologically responding hosts.

In addition, it may be

useful

chem otherapeutic

for

the

evaluation

of

various

and

immunoprophylactic protocols for the control of rapidly evolving viruses.
Thus, an evaluation of the mechanisms involved in the persistence of
EIAV

in

effective

susceptible
disease

horses

control

is paramount
protocols.

in

the

Foremost

eventual

design

of

amongst

these

is

understanding how horsesrespond immunologically to EIAV, and how
1

antigenic drift may be responsible for the recurrence of febrile episodes
in chronic EIA.

The detailed serological and biochemical analyses of

viruses isolated from horses with either acute or chronic EIA may aid in
estimating the degree of antigenic and genetic variation in EIAV.
Equine infectious anemia
are

infected

with

equine

has a variable clinical course.

infectious

anemia

virus

Horses that

(EIAV)

display

a

spectrum of disease conditions that range from an inapparent state to a
chronic

infection

that

is

accompanied

by

recurrent

disease

episodes.

Following primary exposure to EIAV, horses may remain inapparent for
long periods or have an acute disease that may result in death or
recovery.

Horses that survive an acute episode may in turn become

inapparent carriers or progress to a chronic infection.

In natural cases

of EIA a great majority of the horses are inapparent carriers of the virus
and are only discovered when their serum tests positive for anti-virus
antibody (77).
Acute EIA is most often associated with the first exposure to the
virus.

The incubation period varies from 5 days to as long as several

months depending upon the virus isolate used, the amount of virus given,
the host resistance and environmental factors (82).

Pyrexia (>39.5° C),

which lasts for 3 or 4 days, is the most characteristic clinical sign and is
generally evident from 7 to 30 days after infection.

Horses with acute

EIA are often not diagnosed since precipitating antibodies detectable in
the agar gel immunodiffusion (AGID) test peak at about 3 to 4 weeks
after infection

(29).

During the peak of the

febrile response,

high

viremia is often found and viral antigen can be demonstrated in many
body organs, particularly in those rich in macrophages (91, 106).

The

virus is thought to cause a lytic infection of macrophages (87,

106).

Most horses with acute EIA survive and may go unnoticed as the classical
signs of the disease, i.e. weight loss, anemia and ventral edema, are
usually not evident during this first episode (77).
Following
characterized

the
by

initial
the

infection,

occurrence

chronic
of

EIA

may

unpredictable

develop.

recurrent

episodes that may be several weeks to months apart (91).

It

is

clinical

The number

and the frequency of such episodes is variable but tends to decline with
time and about 90% occur within one year of infection (91, 122).

Horses

with chronic EIA are positive in AGID test and depict most of the signs
associated with EIA including fever, loss of weight, weakness, anemia,
ventral edema and terminal depression (122).
The level of cell-free viremia in horses with chronic EIA is variable
but

is highest during the

recurrent febrile

episodes when it reaches

104/m l of plasma for 2 to 3 days before subsiding (91).

Horses with

chronic EIA are apparently normal between febrile episodes; isolation of
virus

from

indicative

plasma

during

of low levels

afebrile

periods

of circulating

is

cell-free

difficult

and

may

be

virus.

The

repeated

massive outpouring of virus and associated antigens in the face of a
vigorous immune response sets in motion a series of immunopathological
events

that cause

the

clinical signs and

lesions of EIA and

include

anemia, infectious immune complexes and glomerulonephritis (67, 107, 139).
Mares that become infected while carrying a foal may either abort or
deliver infected foals depending on the clinical course (81).
unpredictable

number

of recurrent

febrile

episodes,

cycling and remain inapparent carriers of EIAV.

most

After an
horses

stop

However, a number of

EIAV infected horses may fail to show any signs of disease but remain
inapparently infected (77).
a

long

period

episode.

of time

Horses that have been apparently normal for
may

suddenly

re-experience

an

acute

febrile

Moreover, such inapparently infected horses may be induced to

experience clinical EIA by exposing them to environmental stress such as
hard work or by immunosuppressive therapy, such as multiple doses of
dexamethasone (77, 92).

These data all indicate that once horses are

infected they remain virus carriers for life, irrespective of the course of
the disease.
EIAV can be naturally transmitted from
interrupted feeding of horse flies (79).

acutely

ill horses by the

Since the virus has not been

shown to multiply within insects, the only known mode of transmission
other than in utero is mechanical (145).

Mechanical transmission of EIAV

can also be affected by the transfer of blood or blood products on
contaminated

instruments

or

syringes.

The

success

of

mechanical

transmission of viruses depends on many variables including the level of
viremia at the time of feeding (or transfer of body fluids), the survivab
ility of the virus outside the natural host, the population density of both
the natural host and the transmitting insect(s) and the seasonality and
the feeding habits of the insect vector population.

Within the U.S.,

Louisiana has the highest reported incidence of EIA (78).
Diagnosis of EIA currently depends on the detection of precipitating
antibodies in the AGID test, popularly known as the Coggins test (28).
The test is based on the detection of antibodies reactive to the viral
antigens, particularly the major core protein, p26, which contains group
specific determinants.

The correlation between AGID-seropositivity and

the presence of infectious virus in the blood of test horses may approach
100%

(30).

Although other more sensitive serological tests

immunofluorescence (35),

radioimmunoassay (32), and

enzyme

including
linked

immunosorbent assay (140) have been developed, they are rarely used.
Like all other serological tests based on the detection of serum antibody,
the diagnosis of EIA

by AGID is limited to the phase of the disease when

precipitating serum antibody is present.

Other diagnostic procedures that

have been used in the diagnosis of EIA include hematology, pathology,
and the horse inoculation test (77).

RETROVIRUSES AND THEIR CLASSIFICATION.
Retroviruses are classified according to their morphology, the struct
ure of their RNA viral genomes (a dimer of two identical subunits of
single-stranded RNA

(30S-40S) of positive or messenger sense polarity),

and their RNA-dependent DNA polymerase (reverse transcriptase) (47).
Retroviruses

are

mammals, birds,

widely

distributed

among vertebrate

and reptiles (154).

species,

including

The process of reverse transcription

in the expression of genetic information is a strategy utilized not only by
the retroviruses,

but also by hepadnaviruses, as well as viruses infecting

insects and plants (73).
subfamilies:

The family Retroviridae is divided into three

1) Oncovirinae, including all the oncogenic members and

many closely related nononcogenic viruses;
viruses, such as

visna virus; and

2) Lentivirinae, the "slow"

3) Spumavirinae, the "foamy" viruses

that induce persistent infections without any classical disease (154).
Lentiviruses are so named because
incubation periods, insidious

they cause diseases with long

onsetsand slowly progressive courses (61).

The prototype members of this subfamily of retroviruses include a number
of viruses that have been isolated from sick sheep and goats in various
locales.

These viruses include visna, maedi

(59), zwoegerziekte

(40),

progressive pneumonia virus (PPV) (83), and caprine arthritis encephalitis
virus (CAEV) (34).

Other lentiviruses include: equine infectious anemia

virus (EIAV) of horses (15); a number of related retroviruses that have
been isolated from immunodeficient (39) and asymptomatic monkeys (80);
and

the

retroviruses

associated

with

the

acquired

immunodeficiency

syndrome (ADDS) in humans, the human immunodeficiency virus (HIV) (10,
23,27,57)

MORPHOLOGY.
Mature EIA virions are enveloped spherical particles that are 110 to
120nm in diameter (158). The external surface of the virion envelope
contains glycoprotein projections (spikes and knobs) that are 10 to 12nm
in length (158).

The core of the virion is remarkably pleomorphic and

ranges from cone shaped to tubular (158).
located

between

the

core

and

the

An inner particle shell is

envelope.

Ultrastructurally

EIAV

closely resembles visna virus and the other members of the subfamily
lentivirinae

(56).

Recent

subfamily lentivirinae are

evidence

indicates

that

members

of

the

morphologically related and "mature" particles

contain a condensed central core, which depending on the section plane,
appear eccentric, bar-shaped, triangular or oblong (13, 50, 57).
EIA

virions

acquire

their

envelope

by

budding

from

membranes, both into cytoplasmic vacuoles and extracellularly (56).

Mature

cytoplasmic

PHYSICOCHEMICAL PROPERTIES OF EIAV.
The

physicochemical

properties

of EIAV

are

those

of enveloped

viruses in general but those of retroviruses in particular.

Mature EIA

virions are enveloped and have a buoyant density of about 1.16 g/m l in
cesium chloride

(16, 102).

Virion infectivity is sensitive to ether and

detergents but is resistant to trypsin treatment at 37°C, ultra-violet and
X-irradiation (114).

Virus infectivity is inactivated following treatment

with a variety of chemical disinfectants including sodium hydroxide, so
dium hypochlorite, organic phenolic compounds and chlorhexidine (144).
In horse serum, EIAV has been reported to be inactivated by treatment
with 56°C for 60 min (9).

EIAV has been mechanically transmitted to

horses by groups of 25 horse flies 30 min but not 4 hours after they had
taken a partial blood meal from an acutely infected donor (66).
The cell adapted Wyoming strain of EIAV (98) has been the source of
virus for most the majority of published reports on EIAV since 1974.
Purified EIAV has been characterized extensively.

It is composed of the

following: a high molecular weight RNA (60 to 70S) made of two identical
linear subunits that are noncovalently bound near their 5’end; a RNAdependent DNA polymerase (reverse transcriptase) that has a preferential
requirement

for M g + + ;

a lysine-specific tRNA molecule

noncovalently

bound near the 5’ end of each genomic RNA and functions to prime
reverse

transcription

and

6 major structural

polypeptides

those of prototype C-oncogenic retroviruses (6,15,16,112,125).

analogous

to

VIRAL GENOME: STRUCTURE AND EXPRESSION.
The genome of EIAV possesses the three classical genes found in all
replication competent retroviruses (26).

These are the gag gene which

codes for the internal structural proteins, the pol gene which codes for
the reverse transcriptase, and the env gene which codes for the envelope
proteins.
DNA

The transcription of retroviral message proceeds through a
intermediate,

transcriptional

unit

the
that

provirus.
contains

its

The
own

provirus

gene

represents

expression

a

regulatory

sequences within the long terminal repeats (26,155).
Retroviruses are composed of about 60-70% protein, 30-40% lipid, 2-4%
carbohydrate

and

1% RNA (154).

Purified EIAV

contains structural

polypeptides analogous to those of avian and murine type C-oncoviruses
and

include

two envelope glycoproteins and

glycosylated proteins (112, 125).
structural

proteins

electrophoresis

in

The relative molecular weights of EIAV

sodium

(SDS-PAGE)

four major internal non

dodecyl

are

90,000

sulfate

polyacrylamide

daltons

and

45,000

gel

daltons,

respectively, for the two surface glycoproteins (gp), gp90 and gp45 and
core proteins of 26,000,

15,000,

(p26, pl5,

125). In addition to the

pll,

p9)

(8,

11,000 and 9,000 daltons, respectively
six main structural

proteins four minor polypeptides (p70, p61, p30 and p23) are revealed in
SDS-PAGE (125).
virion

reverse

These minor polypeptides could be components of the

transcriptase

or

uncleaved

precursors

for

the

structural

proteins.
The gag gene products are translated from a complete viral messenger
RNA and

processed from a polyprotein (NH2-pl5-p26-pll-p9-COOH) to

form the inner core of the virus (112, 125, 148).

The core of the virus

encloses the ribonucleoprotein complex which is composed of viral RNA,
the basic protein p l l and 6-10 copies of the reverse transcriptase.

The

most abundant structural protein is p26 which forms the core shell with
the acidic protein p9.

The fourth core protein is pl5 which forms a

continuous inner coat or mantle beneath the lipid bilayer (112,125).
The virus glycoproteins are translated from a spliced messenger RNA
that corresponds to the 3’-terminal end of the viral genome and are
subsequently processed from a polyprotein precursor (42).

The env gene,

2577 bases long, encodes the virion envelope glycoproteins in the order
NH2-gp90-gp45-COOH

(135).

Partial

digestion

of purified

virus with

bromelain completely removed the two viral glycoproteins indicating their
location

on

glycoprotein
is

a

less

the

surface

of the

virion

(112).

The

(gp90) is heavily glycosylated (125, 135).
glycosylated

associated with the

and

highly

lipid bilayer

hydrophobic

(125,

135).

major

envelope

In contrast, gp45

glycoprotein

that

is

The spikes and knobs

observed in mature EIA virions represent gp45 and gp90, respectively
(112, 135, 158).
envelope

Analogous to other enveloped virus systems, the major

glycoprotein

of

EIAV,

gp90

probably

mediates

important

functions in the virus replication cycle including host receptor recognition
and may be the primary target for antibody-mediated virus neutralization
(111,

112).

Monoclonal antibodies

infectivity in cell culture (74).

specific for gp90 neutralize virus

It is thus probable that antibodies to

gp90 mediate virus neutralization in vivo.
Apart from the characteristic retroviral genes, gag, pol and env, the
lentiviruses possess other open reading frames whose translation products
may be related to their unique biology.

The EIAV genome contains three

10
such open reading frames SI, S2 and S3 (135) that may have functions
analogous to those documented for HIV (19).
Hybridization studies using cDNA (17,

133) or molecularly cloned

EIAV probes (165) have clearly demonstrated that EIAV is an exogenous
mammalian retrovirus. Moreover, genetic comparisons of EIAV with other
lentiviruses have demonstrated that EIAV is more closely related to this
subfamily

of

retroviruses

than

to

the

oncoviruses

(20,

137,

165).

Furthermore, group specific and interspecies determinants of EJAV cross
react with human and ovine lentiviruses in immunological assays (109, 137,
165).

Sera from horses infected with EIAV recognize the major core

protein, p24 (109) and the major envelope glycoprotein, gpl20 (137) of
HIV-1.

The genetic comparisons of EIAV with

have provided

prototype lentiviruses

more definitive evidence for the assignment „of EIAV as a

lentivirus and confirm earlier assignments that were based on serological
and morphological similarities (6,15,56,57,109).

INTERACTION OF LENTIVIRUSES WITH THEIR HOSTS.
The initial event in the life-cycle of viruses is the attachment to
specific receptors on the cell surface (150).

In many cases, this event is

a major determinant .of virus tropism in pathogenesis (141).

Different

viruses utilize different specialized cell structures as receptors (37): these
viral receptors have important host functions (25) and in most cases
internalize

specific

ligands

by

receptor-mediated

endocytosis

(54).

Lentiviruses infect a variety of cells wherein they cause lytic or persis
tent infections depending on the virus and the cell type.

The prototype

lentivirus visna virus undergoes an acute lytic cycle in cultured sheep

11
choroid plexus (SCP) cells in which the yield of viral progeny is high.

In

the same cell type, CAEV causes a non-lytic infection in which the yield
of progeny virus is 1000-fold lower than that of visna virus (116).

The

cell culture-adapted Wyoming (98) strain of EIAV (prototype EIAV) causes
persistent infections

in equine fibroblasts including those derived

primary fetal equine kidney cell cultures (16).
been

observed

to

cause

cytopathology

in

from

The prototype EIAV has
fetal

donkey dermal

cells

(McManus, unpublished results).
In contrast to the animal lentiviruses, HIV does not infect cultured
fibroblasts and epithelial cells (95).

The restriction of HIV to infect

these cells is predominantly due to the absence of surface receptors.
Transfection of cultured fibroblasts with a molecular clone of HIV
2) showed that the virus can replicate in

(ARV-

cells from several mammalian

species; however, the virus replicated better in human than in mouse
derived fibroblasts (96).

Transfection of tumor cells with the isolated

CD4 complementary DNA demonstrated that CD4 expression was the sole
requirement

for

virus

to

infect

target

lentiviruses

infect

a

variety

of

cultured

lentiviruses

indicate

that

ruminant

infected animal are the
(116, 117).

the

cells

(105).

fibroblasts,

target

Although
studies

cells in

the

monocyte-macrophages and not the

with

the
the

persistently
fibroblasts

However, fibroblasts and possibly other cell types, may be

more involved in the pathogenesis of persistent lentiviral infections than
previously thought.

Indeed, the prototype EIAV can be reisolated in

primary fetal equine kidney cell cultures even after multiple passages in
Shetland ponies (122).
The mononuclear phagocytic system (monocytes and macrophages) is
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considered to be one of the primary non-specific defense mechanisms
against foreign agents including viruses.

In addition, these cells are

involved in the induction, regulation and amplification of the immune
system,

thus

playing

infected host.
to

their

a

central

role

in

eliminating

viruses

from

The ability of viruses to infect these cells may be crucial

persistence

since

latently

presence of neutralizing antibodies.

infected

cells

can

exist

in

reservoir and/or

vehicle

for virus dissemination in an immunologically responsive host (128).
viruses that are capable of
the immune system.
(virus

the

Such latently infected cells may, in a

manner analogous to the Trojan horse, serve as

specific

the

Thus,

invading these cells can very readily evade

Furthermore, these cells can take in viruses by

receptors)

as

well

as

by

non-specific

(Fc-receptors)

mechanisms, thus making them a favorable target cell population for many
viruses.
A

number

of

viruses have a

predilection

for

the mononuclear

phagocytic system wherein virus replication, persistence, and
the

host

occurs

asa

result

of

the

spread in

infection of these cells.

The

monocyte-macrophage series has been implicated in the pathogenesis of
lentivirus

infections

because viral antigens, viral

genomes and/or

replication can be demonstrated in this cell population
techniques

including

immunofluorescence,

ctious

virus

can

be

isolated

from

these

by a variety of

immunocytochemistry,

hybridization, and electron microscopy (86, 106, 128).
cells

by

virus

m

situ

Moreover, infe
cocultivation

with

susceptible cell lines and macrophages readily support virus replication in
vitro (5,51, 95,116)
The unique biology of lentiviruses can best be exemplified by HIV
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which infects a number of cell types and causes an immunodeficiency in
humans that becomes clinically apparent years after the initial infection.
The virus infects a number of cell types that bear the CD4 molecule on
the surface.

HIV infects T4 lymphocytes where it causes lytic or persist

ent infections (10, 14, 38, 48, 72, 85, 105, 129).

The virus also replicates

in non-T lymphoid cell types including normal blood-derived monocytes,
macrophages, EBV-transformed B-lymphocytes, malignant glioma cells and
human monocytoid cell lines (7, 21, 93, 95, 110, 119).
isolated

from

macrophages

human
of

peripheral

AIDS

patients

blood
and

leukocytes
causes

cultured PBLs (21, 49, 93, 95, 119).

a

The virus has been
(PBL)

and

persistent

alveolar

infection

in

This non-cytopathic infection of

monocytes and macrophages is probably due to a lower surface density of
CD4 molecules: the CD4 glycoprotein appears to be an integral component
in HIV-induced cell killing.

However, as these cells harbor HIV proviral

DNA they may serve as a reservoir for virus persistence in the host (58,
86, 93, 143).

Isolates of HIV may differ in their ability to productively

infect human

cells

(46).

As in the

animal lentiviruses,

the

factors

involved in the restriction of virus replication in vivo are not known but
may

include

cytokines

e.g.,

interleukins,

interferons

and

intercurrent

pathogens e.g., EBV, cytomegalovirus and hepatitis B infections.
In contrast to the high yield of viral progeny in vitro, the replication
of lentiviruses is severely restricted

in vivo and withthe exception of

ELA where high levels of plasma

viremia occurduring

episodes,

cell-free

detectable

infections.

In

virus

is

not

ELA, macrophages

are

the

in

clinical disease

the other

lentivirus

only cellsidentified which

harbor the virus and support replication of the wild-type virus (88, 106,
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149).

In some asymptomatic horses infectious virus cannot be demonstra

ted in the serum or whole blood but the infection can be transmitted
with washed leukocytes (31).

Thus, in a manner analogous to the other

lentiviruses, EIAV probably infects many cell types including promyeloc
ytes, monocytes and macrophages (51, 95, 116).

Lentivirus replication

may be intricately associated with the functional status of these cells.
visna,

only

a

small

proportion

of

monocytes

is

infected

and

In
virus

replication is associated with the maturation of monocytes to macrophages
(51, 52).

Virus replication appears to be restricted at the transcription

level (52, 128) apparently through a complex interaction involving infected
monocyte/macrophages,
(118).

T-lymphocytes and

a lentivirus-induced interferon

In infected sheep, virus replication is repressed in many cell types

including

the

antibody (128).

monocyte/macrophages

in

tissue

fluids

with

neutralizing

In a similar manner, HIV genome expression appears to

be repressed and high levels of genome expression are only observed after
prolonged mitogenic stimulation of mononuclear cells from AIDS patients.
The repressed state of lentivirus replication in vivo suggests that these
viruses can persist in the face of a vigorous immune response as most
infected cells are not producing viral antigens and escape detection by
the immune surveillance mechanism.
As with other retroviruses, lentiviruses can persist in susceptible cells
by integrating their DNA proviruses into host cell DNA (155).

Once

integrated, the provirus is replicated and duplicated equally to daughter
cells along with the host
genome.

In

lentivirus

DNA, thus ensuring survival of the viral
infections,

both

integrated

and

unintegrated

proviruses have been demonstrated in cultured cells and in cells or tissues

from infected individuals (17, 65, 133, 142, 164).

The replication cycle of

visna virus in cultured cells occurs without provirus integration (65).

The

biological significance of the level of provirus integration observed in
lentivirus infections is not known but may

be related to the exogenous

nature of this subfamily of retroviruses (62).

ANTIGENIC VARIATION
The

survival

of

parasites

in

their

target

hosts

is

continuously

challenged by the immunological mechanisms involved in host protection.
Faced with these immunological barriers, parasites have improvised growth
strategies

whose

sum

enable

them

to

persist

in

their

hosts.

The

repertoire of these growth strategies includes: partial or complete genetic
changes

involving parasite

surface

structures;

growth

in

cells

of

the

immune system including lymphocytes, monocytes and macrophages; growth
in parts of the body with less vigorous immunological surveillance (e.g.
CNS); and an inability to express parasite antigens for long periods, i.e.
latency.

The

consideration

games
of

the

that

parasites

survival

play

are

mechanisms

best

exemplified

displayed by

the

by

a

African

trypanosomes and the influenza virus.
The antigenic properties of the African trypanosomes are due to a
single

glycoprotein,

trypanosome

contains

serologically

and

the

variant
over

biochemically

surface

100

VSG

glycoprotein
genes

different(11).

(VSG).

whose
Antigenic

Each

products

are

variation,

mediated by sequential expression (via DNA recombination) of the VSG
genes, is the primary mechanism for the survival of trypanosome popula
tion in immunologically responding hosts.
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Viruses with RNA genomes evolve by a variety of means.

These

include reassortment of gene segments, recombination between homologous
nucleic acid molecules, point mutations, sequence repetition, deletion and
inversion.

Reassortment of virus genomes occurs with viruses that have

segmented genomes regardless of their strandedness or complement of
strand segments (124).
there

can

be

an

If cells are infected with two related viruses,

exchange

of

homologous

gene

segments

with

the

production of different stable reassortants.
Two distinct kinds of antigenic variation have been demonstrated in
influenza A viruses; antigenic shift and antigenic drift.
type A influenza virus occurs infrequently
appears

Antigenic shift in

when a "new" virus suddenly

with hemagglutinin (HA) and/or neuraminidase (NA) molecules of

a subtype different to those of the virus circulating before the new virus
appealed.

Antigenic

shift

is

thought

to

occur

when:

1)

genetic

reassortment occurs between human and animal or human viruses; and 2)
animal or bird influenza A viruses undergo mutations which allow them to
become infectious for humans (3).
At

more frequent intervals, minor changes termed

antigenic drift,

take place in one or both of the surface glycoproteins (HA and NA).
Antigenic drift in influenza A virus occurs by point mutations in the HA
and NA genes that lead to a gradual accumulation of amino acid sequence
changes that alter the epitopes in such a way that they no longer are
recognized by existing specific immune effector mechanisms.

Although

each episode of drift may be minor, the effects are additive and over a
period of several years result in a virus showing a considerable degree of
antigenic

difference

from

the

original

pandemic

virus.

The

point
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mutations are predominantly in the amino terminal end of the HA gene
and

cluster

Antigenic

to

four

analysis

polyspecific

antisera

of

antigenic
HA
revealed

sites

with

in

the

monoclonal

that

native

HA

antibodies

epidemiologically

polypeptide.
(MAbs)

significant

and
strains

sustain point mutations at two or more antigenic sites; a large number of
mutations are required for complete resistance to polyspecific antisera (3,
12,146,157,167).
In visna, new virus strains do not successively replace parental virus;
both the inoculum strain and

the variant strains can be isolated from

peripheral blood leukocytes simultaneously.

The

new strains of visna

virus have been shown to arise by point mutations in the env gene which
result in structural alterations in the major envelope glycoprotein, gpl35
(24, 138).

In most cases, visna virus persists and spreads without the

emergence of new virus variants (97, 153).

Besides the repressed state of

visna virus genome expression in monocyte/macrophages, visna virus can
infect these cells in the presence of "neutralizing" antibodies indicating
that antigenic variation is not critical for the survival of this virus in
immunocompetent hosts (84).
In chronic EIA there are cycles of virus replication in which
can be isolated from plasma.
obtained

virus

Neutralization studies using polyclonal sera

from rabbits immunized with purified virus demonstrated the

existence of antigenic drift in EIAV (91).

Each new virus isolate from a

cycle is refractory to neutralization by antibody that neutralized previous
EIAV isolates (91, 123, 136).

Recent studies have further documented

that viruses recovered from sequential febrile
and genetically unique (127, 136).

episodes are

structurally

Western blot analyses of EIAV isolates
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revealed that antigenic alterations occurred predominantly in the major
envelope

glycoprotein,

gp90

(74).

The

survival

immunologically responsive hosts appears to be
variation.

of

mediated

EIAV

in

by antigenic

From this standpoint, it is imperative to determine the extent

to which this virus varies and exists in susceptible animal populations
before any immunoprophylactic or chemoprophylactic intervention can be
contemplated.
The contention that lentiviruses demonstrate rapid genomic changes
has recently been extended by

results from the analysis of HIV isolates

obtained from the same or different individuals (64, 163).
HIV-1

isolates

genomic

from

variation

different

particularly

geographical
within

envelope glycoprotein (4, 63, 162, 163).
observed

in

individuals (64).

viruses

sequentially

the

regions
region

Analysis of

revealed
encoding

extensive
the

viral

A similar variability has been

isolated

from

persistently

infected

Viruses isolated from one individual are more genetically

related to each other than to viruses isolated from other individuals and
may therefore have evolved in parallel from a common progenitor (64,
163); virus interference may exclude superinfection with many strains of
HIV.

The genetic variability of HIV results largely from small duplica

tions, insertions or deletions as well as from numerous point mutations in
the envelope gene (63, 63, 162).

Within the env gene, hypervariable

regions are interspersed with regions of strong conservation (131, 147,
162).

Complementing the sequence data, serological studies have shown

that HIV-1 isolates are antigenically heterogeneous (22, 103, 159).

HIV-2

is

simian

genetically

and

antigenically

more

closely

related

immunodeficiency virus (SIV) than to HIV-1 (23, 60).

to

the

Molecular and
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serological data indicate that

HIV is as highly

mutable as the animal

lentiviruses (24,127).
Like RNA viruses in general, lentiviruses have high mutation frequen
cies due to the lack of error correcting mechanisms in genome replication
(132).

The estimated error rate for RNA replicases lies between 103 and

10-4

(71, 132) and is therefore of the order of 104- to lOMbld greater

than the mutation rates of stable DNA genomes

(69, 71).

Replication of

RNA is therefore an intrinsically "noisy" process (132).

The noisiness of

RNA

viruses

replicases

monolithic,

but

means
are

that

the genomes

constantly

evolving

of

RNA

irrespective

homogeneity of any starting virus population (69).

of

the

are

not

attested

Analyses of lentivirus

genomes by Tl-oligonucleotide mapping, Southern blot, restriction enzymes
and

nucleotide

slight

to

rather

sequencing reveal

that

extensive changes;

genomic variations

such

changes

are

range from

observed

with

highest frequency in the env gene and are compatible with the expected
mutational rates of RNA viruses (64, 113, 136, 163).

These genomic

changes may result from errors associated with reverse transcription and
from genetic recombination during mixed infections with related viruses.
The viral glycoproteins are involved in host-cell recognition and may
be the primary targets for antibody mediated neutralization.
envelope

glycoproteins

in

eliciting

neutralizing

antibodies

The role of
has been

established for a number of viruses including feline leukemia virus gp-70
(121),

influenza virus hemagglutinin (156), herpes

tein-D

(33), rabies virus glycoprotein-G (161), human immunodeficiency

virus gpl20 (160) and EIAV gp90 (74).
point

of view, knowledge

of

simplex virus glycopro-

Thus from an immunoprophylactic

the structure, immunogenicity, antigenicity
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and variability of the surface glycoproteins of lentiviruses is imperative.
Specific

antibodies

mechanisms.
involves

First,

loss

of

exert

intrinsic
virus

antiviral

effects

neutralization

infectivity

may

mediated

antibody to neutralization antigenic sites.

via

several

occur.

by

the

This
direct

distinct

mechanism
binding

of

In some cases, bound antibody

may mediate neutralization only in the presence of complement or anti
globulin.

Second, extrinsic neutralization may result in the loss of virus

infectivity due to an inhibition of virus adsorption which results from
antibody

binding

at

or

nearby

the

viral

attachment

proteins.

In

enveloped viruses, antibodies attached to the envelope glycoproteins can
also

mediate

membrane.

neutralization by complement-mediated

lysis of the virus

A third mechanism, pseudoneutralization, which may function

under certain conditions, e.g., at equivalent concentrations of virus and
antibody, results in loss of virus infectivity by promoting formation of
lattice like aggregates of infectious virions.
IgM and

early IgG

Moreover,

the

cell

tend
type

to
and

Low affinity antibodies e.g.,

have higher levels of "sensitized" virus.
the

environmental

conditions

may

also

contribute to this phenomenon (43,104, 111, 120).
Antibodies

can

neutralize

poliovirus

changes in the capsid (44, 45, 99).
alteration

of

molecular

adsorption to host cells.

functions

by

inducing

conformational

These changes may result in an
including

loss

of

efficient

virus

Cross-linkage of pentameric subunits of the

virus capsid (76) or aggregation of virus particles (2) result in poliovirus
neutralization.

Conformational alterations in the viral capsid may result

in the physical loss of viral genome causing irreversible loss of infectivity
as exemplified by foot-and-mouth disease virus (104).
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Although the attachment of virus to host cells can be prevented by
neutralizing antibody, e.g. reovirus

infection of L-cells

(94), in

most

cases, the binding of neutralizing antibodies to virions does not inhibit
virus attachment to host cells.
site is distinct

from the

influenza virus (134).

This may be because the cellular binding

epitopes

involved in

neutralization, e.g.

with

Antibodies that neutralize influenza virus do not

inhibit attachment, penetration, uncoating of virus or transport of the
uncoated

RNA

into the nucleus.

Moreover,

the mechanism of

neutralization may depend on the antibody isotype.

virus

Thus, monomeric IgG

probably neutralizes influenza virus by inhibiting the function of the viral
transcriptase (130), while polymeric IgA and IgM may neutralize the virus
by steric hinderance of the viral receptor "pocket" in the HA (151, 152).
Antibody induced conformational changes may result in the neutralization
of enveloped viruses by inhibition of a low-pH mediated fusion reaction
between the membrane of the virus particle and that of a prelysosomal
endosome, thus impairing the entry of viral cores into the cytosol as has
been shown with the West Nile virus (55).
of the

varibus

immunoglobulin

classes,

The different modes of action
the

different

viruses

and

the

different cell systems used by many investigators may help to explain why
virus neutralization is still a controversial subject.
It is generally accepted that immune selection pressure operates in
the selection of virus mutants during antigenic drift.

Antigenic drift has

been mimicked in the laboratory by the propagation of viruses in the
presence of low levels of neutralizing polyclonal antisera or monoclonal
antibodies.

Such studies have been conducted for a number of human and

animal viruses including the human influenza A viruses (53), poliovirus

22
type 1 (41), herpes simplex virus (70), foot-and-mouth disease virus (75),
and visna virus (115).

A general outcome of propagating these viruses in

the presence of neutralizing antibodies has been the emergence of virus
variants that resisted neutralization by the selecting antibody.

Chronic

EIA, characterized by recurrent febrile episodes, is thought to be induced
by novel virus variants (90) that probably arise through random virus
genome mutations and antibody selection pressure.
neutralization

escape

substantiating the

mutants

role

of EIAV

in

Thus, generation of

cell culture

would

of antibody in antigenic drift.

aid

in

Antigenic and

genetic analysis of neutralization escape mutants may identify the changes
associated with the ability of virus variants to elude host immunological
controls.
In infections of horses with EIAV, serum neutralizing antibodies have
not been detected earlier than 45 days after infection and peak titers
occurred later in the course of the disease (89).

This raises the

question of the nature of both specific and non-specific immunological
controls operative in the recovery from acute EIA in the absence of
demonstrable

neutralizing

antibody. Furthermore,

the

effectiveness

of

neutralizing antibodies is periodically circumvented by the ability of the
virus to change antigenically (90) thus allowing virus mutants to replicate
until immunological controls are reestablished.
chronic

EIA

inapparently
relatedness

cease
infected

to have
for

recurrent
life.

febrile

It is not

exists between viral isolates.

Eventually, horses with
episodes

clear how
If present,

but

much

remain

antigenic

it is apparently

minor and inadequate to stimulate cross-protection by antibody (90, 91).
Most horses mount a vigorous humoral and cell-mediated immune
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(CMI) response to most if not all EIA antigens and CMI may be the
principal

mechanism

recurrent EIA (108).

involved

in

long

term

host

protection

against

Indeed, when asymptomatic horses were treated with

dexamethasone or cyclophosphamide, viremia and clinical disease occurred
(92).

The time interval between treatment and disease expression was too

short to be explained by an effect on antibody levels.

Furthermore,

horses with chronic EIA resisted infection by serotypes to which they had
no demonstrable neutralizing antibody, which
factors

other

than

antibody

suggests that immunological

participate

recurrent febrile episodes (90).

in

protecting

horses

from

In viral infections, a T-cell mediated

immune response may be the most important regulator of the host to
infection.

Thus, the induction of a CMI response may be an important

component of the overall immunity directed towards viruses.

Although

definitive mechanisms of CMI responses have not been obtained in EIA,
evidence from influenza virus indicates that viral envelope glycoproteins,
as well as internal viral proteins, are
cross-reactive

involved in the generation

cytotoxic

T

lymphocytes

of

serotype-specific

and

(CTLs),

respectively (1).

Although the internal viral proteins are involved in the

generation of cross-reactive CTLs, vaccination of mice with recombinant
vaccinia virus containing the nucleoprotein (NP) of influenza virus did not
induce

complete

protection

(167)

indicating

that

HA

is

required

for

complete protection to occur; this implies that strain specific neutralizing
antibodies

and

CTLs

are

important

in

the

primary

defense

against

influenza virus infection.
A major challenge in the control of viruses that evolve as rapidly as
EIAV is development of effective vaccination protocols.

A combination of
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molecular and genetic studies of the lentiviruses has shed light on some
unique
rapidly.

properties

of

these

viruses,

especially

their

ability

to

evolve

However, fundamental aspects of the mechanisms by which these

viruses are transmitted from host to host and how they persist within
immunoresponsive hosts need to be identified. A better understanding of
the pathogenetic mechanisms of EIAV and the immune responses important
in host protection is desirable for a rational assessment of strategies for
vaccine development.
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RESEARCH OBJECTIVES.
Equine

infectious

throughout the world.

anemia

is

a

disease

horses

that

occurs

The disease tends to have a recurrent course and

infected horses carry the virus for life.
thought

of

Recurrent episodes of EIA are

to be due to the emergence of

escape immunological controls

novel variants of EIAV that

existent at the time of their emergence.

Recent studies have shown that EIAV mutants readily evolve in infected
animals.

To

date,

no

form

of

is in use.

chemotherapeutic

intervention

in EIA

For any of these

anticipated

or even attempted, a detailed

or

immunological

measures

to

be

analysis of the mechanism(s)

involved in the persistence of EIAV needs to be achieved.

Thus, an

assessment of the repertoire of serotypes of EIAV and their relatedness
to each other is central to any attempt to control this important viral
disease of horses by vaccination.
were generated

To address this issue, virus variants

in Shetland ponies.

For this study, the cell culture

adapted Wyoming strain of EIAV (98) was used at its second passage in
Shetland ponies to infect a series of third passage recipients.

EIAV

isolates obtained from these ponies during febrile episodes were charac
terized by serological and biochemical methods.

The following is an outline of the research objectives:
1.

Generate a panel of EIAV variants in Shetland ponies.
a.

Isolate EIAV from acute-phase plasma by end-point dilution in
fetal equine kidney cell cultures.

b.

Characterize the virus isolates in cross-neutralization assays using
a panel of EIA convalescent sera

and rabbit hyperimmune sera

against lentil-lectin affinity purified EIAV glycoproteins.
c.

Analyze these

viral isolates in Western immunoblots and

using a panel of MAbs and convalescent antisera.

d.

Analyze viral

glycoproteins

by

two-dimensional

tryptic-

peptide mapping.
Isolate neutralization escape mutants using neutralizing convalescent
sera. Analyze these mutants in:
a.

Western blot using convalescent sera and MAbs.

b.

Neutralization

by

heterologous

convalescent

sera

and

the

glycoprotein specific antisera.
Document

the

kinetics

of

anti-EIAV

humoral

responses

during

persistent infection.
Evaluate

a

single-step

immunoblot

antigen detection, respectively.

assay

for

EIAV

antibody

and
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CHAPTER TWO

EQUINE INFECTIOUS ANEMIA VIRUS (EIAV): HUMORAL RESPONSES AND
ANTIGENIC VARIATION DURING PERSISTENT INFECTION IN PONIES.

SUMMARY
Three Shetland ponies (A, B and C) were inoculated with plasma from
a pony with clinical signs of equine infectious anemia (EIA) and observed
for

165 to 440 days.

Clinical signs of EIA marked by high fever

( 39.5°C) lasting 2-4 days were observed 2-3 weeks after infection and
one to four such episodes occurred in each pony.

EIAV was reisolated

from the plasma of each pony by end-point dilution in fetal equine kidney
(FEK) cells and a plasma viremia
each episode.

103-5 TCID50/m l was observed during

Cross-neutralization tests with sequential serum samples

showed that the four viruses isolated from pony A during febrile episodes
4-5 weeks

apart were

serologically

different.

Two-dimensional

tryptic

peptide analyses of the envelope glycoproteins of four isolates from pony
A revealed additions or deletions between each isolate and its immediate
predecessor.

Western blot analyses of these four isolates including those

from ponies B and C with a panel of monoclonal antibodies demonstrated
antigenic variation in both gp90 and gp45.

Both conserved and variable

epitopes were identified in each glycoprotein with greatest variation in
gp90.

Specific IgG directed against determinants of EIAV gp90, gp45 and

p26 was detectable by AGID and Western blots within one month after
infection.

These antibodies appeared to react with conserved antigenic
50
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determinants

of these proteins

as

heterologous virus isolates alike.

they reacted with

homologous

and

The group-specific determinants of gp90

and gp45 were more antigenic than those of p26.

The ability of "early"

sera to recognize determinants on all EIAV isolates did not correlate with
their

ability

antibodies,

to

first

neutralize
detectable

the
within

infectivity
two

of

months,

EIAV.
were

Neutralizing
observed

to

be

effective only to viruses isolated prior to serum collection but became
broadly reactive later in the infection regardless of the number of clinical
episodes.
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INTRODUCTION
Equine

infectious

m orphological,

anemia

serological

virus

(EIAV)

and

genetic

a

lentivirus

similarity

that
with

shares
human

immunodeficiency virus (HIV) (8, 19, 33, 34) causes a lifelong persistent
infection in horses often
fever (3, 12).
targets

for

characterized by recurrent episodes of high

Major virion envelope glycoproteins present the principal
immune

attack

against

retroviruses

(32).

Monoclonal

antibodies to some epitopes of the major envelope glycoprotein of EIAV,
gp90, have been shown to neutralize virus infectivity (11).

In addition to

their

as

integrated

immune

responses

ability

proviruses,

as

the

retroviruses
lentiviruses

to

persist in

their

hosts

further

elude

protective

because the antigenic structures of the surface glycoproteins change (11,
22, 30, 31).

Biochemical analyses of the env gene of the lentiviruses

have demonstrated marked variability

particularly in the region coding

for the outer envelope protein (4, 9, 10, 27, 28, 35).
variation

common

in

the

lentiviruses

suggests

vaccines for these viruses will be difficult.

The rapid antigenic

that

development

of

In EIAV, where genomic

variations often result in the emergence of antigenic variants that cause
recurrent

febrile

episodes

(16,

26,

27, 28),

the

extent

of

antigenic

variation needs to be determined with the hope that suitable immunogens
can be identified.
To extend our previous studies on the antigenic variation of EIAV,
seven

virus

isolates

recovered

from

persistently

infected

analyzed by cross-neutralization with convalescent sera.

ponies

were

To determine

the changes that occur in EIAV proteins during antigenic variation, the
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envelope

glycoproteins

of

the

dimensional tryptic peptide

virus

isolates

were

analyzed

in

two-

maps, Western blots with homologous and

heterologous equine sera, and a panel 18 monoclonal antibodies.

The

results document the generation of group- and type-specific antibodies to
EIAV glycoproteins and extend our previous data indicating that during
persistent

infections

the

virus

undergoes

rapid

antigenic

variation

by

altering the structure of the envelope glycoproteins.

MATERIALS AND METHODS
Animals and viral challenge:

Serial passage of the prototype cell adapted

Wyoming strain of EIAV (18) in Shetland ponies and the isolation of virus
from plasma has been previously described (23).

In this study, plasma

obtained during the first febrile episode of a second passage recipient
pony (#82) was used as source of challenge virus (23).

This plasma has

been the source of several well characterized antigenic variants of EIAV
(11, 27, 28, 31).
(subsequently
inoculated

Briefly, three Shetland ponies F135, P135 and P130

referred

to

as

intravenously with

A,

B,

and

approximately

C,

respectively)

104-8 median

infective doses (TCID50) of EIAV in plasma.

were

tissue

each
culture

Rectal temperatures were

daily recorded for a period ranging from 165 to 440 days post inoculation
(DPI).

Plasma samples obtained during febrile episodes ( 39.5°C) (Figure

1) were the source of EIAV isolates used in this study.

Virus isolation, production and purification:

Isolation of virus from

plasma and propagation were performed in fetal equine kidney (FEK) cell
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cultures using previously described methods (20, 23).

The predominant

virus in each febrile episode was isolated by end-point dilution in FEK
cell cultures.

Production of EIAV antigen in these cells was monitored in

an agar gel immunodiffusion (AGID) test (1).

End-point diluted viruses

were produced in FEK cell cultures and purified on 20-80% glycerol
- gradients according to previously described methods (20,24).

Equine convalescent sera:
ponies
isolates

and
in

naturally

Sera collected from experimentally infected

infected

neutralization

horses were

and

used

immunoblot

to

characterize

assays.

Sera

virus
from

experimentally infected ponies were collected between febrile episodes and
during the afebrile periods.

Sera from naturally infected horses were

selected from horses known to be infected (by AGID test seropositivity)
for over 10 years.

Detection of antibodies to EIAV:

Antibodies to EIAV were detected in

the agar gel immunodiffusion (AGID) test using approved protocols (29)
and commercially available reagents (Pittman-Moore, Washington Crossing,
NJ), in virus neutralization and in immunoblot assays.

Virus neutralization assay:

The

neutralizing

activities

of

convalescent

sera were determined in FEK cell cultures using the alpha-method of
virus neutralization.

Viruses isolated from plasma were reacted

serum collected both before and after each febrile episode.

with

Serial 10-fold

dilutions of each virus were mixed with a standard dilution (1:4 in MEM)
of heat inactivated (56°C, 1 h) serum.

The virus-serum mixtures were
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incubated at 37°C for 1 h and assayed for residual infectious virus by
inoculating duplicate FEK cell monolayers with 1 ml aliquots.

Controls

consisting of mixtures of virus dilutions with MEM were included for each
test.

For virus adsorption, inoculated cultures were incubated at 37°C

for 1 h.

Maintenance medium (5 ml) was added to each culture and

incubation at 37°C was continued for 3 weeks when cultures were assayed
for virus antigens according to previously described methods (1).

The

neutralization index for each serum was calculated as the difference in
virus

titre

without

serum and that

of the

virus-serum mixture.

A

neutralization index of 1.7 was considered positive.

Monoclonal antibodies:

The isolation and characterization of a panel of

monoclonal antibodies (MAbs) to glycoproteins of prototype EIAV has
previously been described (11).

These and other MAbs were used to

determine the antigenic changes in seven EIAV isolates.

Two-month old

BALB/c mice were immunized with purified EIAV isolate A /1
previously described protocols (11).

using

Production of anti-virus antibodies

was monitored in an indirect enzyme-linked immunosorbent assay (ELISA).
Mice were sacrificed 3 days after the final boost and their spleen cells
.fused with

SP2/0 myeloma cells in the presence of PEG

RPMI-1640 medium) (7).
production

(50% PEG in

Hybridomas were screened for specific antibody

in ELISA (11) and Western blots and those

secreting

viral

glycoprotein specific antibodies were subcloned twice by limiting dilution.
Ascites was obtained in pristane primed mice as previously described (11).
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Immunoblot analysis of EIAV isolates with equine sera and MAbs:

EIAV

proteins were separated on 7.5 to 20% gradient gels in discontinuous
buffer

under

reducing

conditions

(17)

and

blotted

onto

membranes using previously described methods (2, 13).

nitrocellulose

The nitrocellulose

membranes were blocked for 2 h with 5% BLOTTO in TBS (lOmM TrisHCL, 0.9% NaCl, pH 7.4) to prevent non-specific binding of antibody (14)
and incubated with MAbs (1:20 dilution of ascites or 1:4 dilution of tissue
culture fluid) or equine serum (at indicated dilutions) for 2 h.

All

incubations with antibody or with TBS containing 0.05% Tween 20 (SIGMA
Chemicals, St. Louis, MO.) were done at 37°C with agitation.

After a 20

minute wash in TBS/Tween 20 the membranes were incubated for 1 h with
horseradish peroxidase labeled
anti-mouse

immunoglobulins

second antibody.

(CAPPEL,

COOPER

Affinity purified goat
BIOMEDICAL

INC.,

MALVERN, PA) or rabbit anti-horse IgG (MILES-YEDA LTD, ISRAEL)
were used at a dilution of 1:1000 or 1:3000, respectively.

After two

washes (final wash with TBS) bands specifically recognized by equine sera
or

monoclonal

antibodies

were

developed

with

4-chloro-l-naphthol

in

methanol (Bio-Rad, Richmond, CA).

Glycoprotein purification and peptide mapping:

E IA V

glycoproteins

(gp90 and gp45) from isolates A/1-4 were purified on lentil-lectin affinity
columns as previously described (21).

Affinity purified glycoproteins were

separated on discontinuous 10% SDS-PAGE (17).
gp90 and

gp45 were

radioiodinated

and

Gel slices containing

digested with

trypsin.

The

released radioiodinated peptides were analyzed by two-dimensional thin
layer chromatography and

detected by autoradiography with Kodak X-
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Omat film (XRP-5) (5,6,22,31).

RESULTS

Persistent infection in Shetland ponies.
First febrile episodes (defined as

39.5°C for 2 or more days) were

observed between 16 and 19 DPI (Fig 1).

Antibodies to EIAV antigens

were detected in AGID on 25 DPI (A and B) and 29 DPI (C).
first

febrile

episode

the

clinical

course

of the

disease

After the

was

variable.

Ponies A and B had four and two febrile episodes, respectively, and pony
C

had only one febrile episode (Fig. 1).

The duration of

the febrile

episodes ranged from 2 to 4 days and each episode was characterized by
high

fever,

depression,

inappetence

and

general

episodes occurred within four months of infection.

weakness.

All

the

Ponies A and B died

on 280 and 165 DPI, respectively, after several days of severe illness
marked by depression, anorexia, loss of weight, prostration and diarrhoea.
Pony C was euthanatized on 440 DPI after a similar severe illness.

to

Plasma samples collected during febrile episodes contained

from 103-5

104-5 TCID50 of EIAV per ml (Fig 1).

isolates of

A total of seven

EIAV were recovered from plasma by end-point dilution in FEK cell
cultures; virus isolates from sequential episodes from the same pony are
numbered

sequentially,

characteristics

of

these

e.g.

A/1,

A /2

viruses were

etc.

(Fig

analyzed

in

1).

The

serologic

neutralization

assays

with convalescent sera, immunoblots with homologous and heterologous
convalescent

sera

and

MAbs.

The

structural

glycoproteins were analyzed by tryptic peptide maps.

alterations

of

EIAV
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Immunoblot analysis of equine sera during
persistent infection with EIAV.
The protein binding specificities of sera collected during persistent
infection with EIAV were analyzed in immunoblot assay.

To obtain

maximum transfer of gp90 and gp45, electroblotting from SDS-PAGE gels
to nitrocellulose membranes was continued for 22 h at 75 V.
shorter

transfer

times,

immunoreactivity

with

gp90

was

less

With
intense.

Preinoculation sera were negative for EIAV specific antibodies (Fig. 2
panel A).

Serum collected after the first febrile episode from pony A at

35 DPI had detectable activity to EIAV gp90, gp45 and p26 of isolates
A/1, A /4 and prototype EIAV (Fig 2 panel B).

The predominant activity

was to the major envelope glycoprotein gp90 and the major core protein
p26 at the 1:50 dilution used (Fig 2 panel B).
activity with the other 5 isolates.

The serum had similar

Comparison of the seven isolates with

prototype EIAV in SDS-PAGE showed minor variation in the rate of
migration of the envelope glycoproteins with no variation in the migration
of the core proteins (data not shown).

Serum collected at 203 DPI

contained high levels of antibody that bound extensively with gp90, gp45
and p26 (Fig. 2 panel C).
dilution used.

Several other bands were noted at the 1:100

As the level of IgG to these minor bands was generally

low in infected horses, only those bands corresponding to gp90, gp45 and
p26 were considered in the evaluation of humoral responses to EIAV
isolates.

Sera from naturally infected horses reacted with determinants

of gp90, gp45 and p26 in the same viruses with levels of p26 activity
lower than those to the envelope glycoproteins in most samples (Fig. 2
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panel D, and Fig. 3).

Immunoblot analysis using serial dilutions of both

35 DPI and 203 DPI sera indicated that the envelope glycoproteins are
more highly immunogenic relative to their mass in the mature virion
(Table 1).

Immunoblot analysis of EIAV isolates with MAbs to gp90 and
gp45.
The antigenic alterations in gp90 and gp45 during persistent infection
were analyzed with MAbs.

The activity of MAbs to gp90 (Fl-120 and Fl-

123) and gp45 (Fl-106, Fl-102 and Fl-110) of isolate A /1 was tested
against seven virus isolates including the prototype cell adapted EIAV
(Table 2).

The activity of these MAbs was analogous to that of MAbs

previously shown to recognize epitopes 90-A and 45-A, respectively (11).
As these MAbs appeared to be directed against highly conserved epitopes
of EIAV they were grouped with those mapping to epitopes 90-A and 45A, respectively.

Analysis of viruses isolated from sequential and parallel

febrile episodes with MAbs to prototype EIAV demonstrated the presence
of variable and conserved epitopes in gp90 and gp45, respectively (Table
3).

The previously described classification of epitopes in gp90 (A-F) and

gp45 (A-B) (11) was used in this study.

Epitope 90-E was not detected in

blots with all the seven virus isolates.

The greatest antigenic variation

was observed in the major envelope glycoprotein, gp90.

Appearance and specificity of EIAV neutralizing antibody.
Neutralizing activity was present in all three ponies by 67 DPI and
was

effective

only

for

homologous

virus

isolates

recovered

prior

to
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collection of the serum, i.e. 16 or 46 DPI (Table 4).
with

sequentially

collected

sera

showed

that

Cross-neutralization

isolates

A / 1-4

were

serologically different.

Serum collected from pony A later in the course

of

203 DPI, had

infection,

i.e.

at

neutralizing activity for

isolates recovered earlier in the infection (Table 4).

all virus

Similar neutralizing

activity was observed with sera collected from pony B.

Serum collected

from pony C late in the infection (438 DPI) neutralized several isolates of
EIAV including the prototype virus (Table 5).
of

438

DPI

serum

was broad but

could

The neutralization activity
still distinguish

serological

differences between the panel of virus isolates tested (Table 5).

The

specificity of neutralizing antibodies in late serum was broad and did not
correlate with the number of sequential febrile episodes observed.

Analysis by peptide mapping.
The structures of the envelope
recovered

from

sequential

febrile

glycoproteins of four virus isolates
episodes

dimensional tryptic peptide mapping procedures.
gp90 components of isolates A /l-A /4

were

analyzed

by

two-

The peptide maps of the

(Fig. 4 row' A) indicate peptide

additions and deletions when each virus isolate is compared with its most
immediate progenitor.

Thus, A /2 is compared to A/1, A /3 to A /2 and A /4

to A /3, respectively.

The results of each comparison revealed differences

in the peptide maps of each pair examined.
examined,

isolate

A /4

had

Between any two pairs

the greatest number of peptide

additions.

Peptide maps were also obtained for the respective gp45 components of
isolates A /l-A /4 (Fig 4 row B).

Again pair-wise comparisons of the gp45

peptide maps revealed the presence of additions and deletions.
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DISCUSSION
Our data on the antigenic variation of EIAV are in agreement with
previous reports (11, 16, 22, 27, 28, 31).

We further show in this report

the kinetics of humoral responses to EIAV during experimental infections
and extend our previous data on the antigenic and structural alterations
occurring in the envelope glycoproteins during persistent infections.
In this study, the decline of viremia did not correlate with detection
of

antibodies

capable

of neutralizing

EIAV

in

equine

fibroblast

cell

cultures.

Neutralizing activity was detectable within two months and was

effective

against

episodes

suggesting that

The

occurrence

neutralizing

only

of

those
the

recurrent

antibodies

viruses

recovered

during

prior

febrile

neutralizing antibodies were type specific.
febrile

observed

episodes

during

and

chronic

the
EIA

specificity
suggest

of
that

conserved antigenic determinants detectable in the envelope glycoproteins
do not elicit sufficient protective immune responses.

The specificity of

neutralizing antibody observed in vitro broadened during the course of
EIA suggesting that multiple stimulation of the immune system with one
or more EIAV strains was necessary to generate this activity.
are

in agreement with those of Kono et al.

neutralizing

antibody

as

assayed

in

horse

These data

(15) who showed that

leukocyte

cultures

appeared

from 45 to 87 DPI and reached peak titers from 90 to 148 days.

The

rapid appearance of high levels of neutralizing antibodies to the isolates
recovered after 45 DPI is suggestive of either immunological priming with
heterologous isolates or the presence of sensitizing levels of homologous
isolates preceding each recurrent febrile episode.

These studies showed

that the neutralizing activity persisted for a long time.

Although all
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three ponies died within one and half years after infection despite the
presence of potent neutralizing antibodies, several ponies infected with
the plasma used in this study have lived for over 8 years suggesting that
early death may have been due to other causes.
The envelope glycoproteins of prototype EIAV and the seven isolates
in this study contain highly antigenic group-specific determinants which
in immunoblot assays reacted strongly and more consistently than those
associated with the major core protein, p26.

This and other studies (13)

have shown that in many naturally infected horses, antibodies to the viral
core proteins are often undetectable in Western blots when serum is
diluted

1:50.

In contrast, activity with the envelope glycoproteins was

uniformly detected in sera with positive AGID results.

No correlation was

detected between the length of infection and the levels of antibodies to
the core proteins.
from

The lower levels of antibodies to p26 could result

abundant production

of core proteins

that may remove

specific

antibody from circulation.
We have previously demonstrated that virus isolates recovered from
ponies

inoculated with

the virus

strain used

in

this study could be

distinguished with panels of MAbs to gp90 and gp45 of EIAV (11).

Both

conserved and variable epitopes have been identified in gp90 and gp45,
respectively (11).

Analysis of seven isolates with the same panel of MAbs

demonstrated antigenic variability in gp90 and gp45.

Most of the epitopes

in gp90 were variable and appeared to evolve randomly.

The antigenic

variation occurred both before and after the appearance of detectable
neutralizing antibodies suggesting that selection processes other than by
neutralizing antibodies are involved in EIA.

Similar observations have
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been

m ade

in

other

studies

oligonucleotide, peptide and
from febrile
31).

which

demonstrated

nucleotide,

glycopeptide variation in isolates

recovered

episodes that occurred 2-3 weeks after infection (22, 27, 28,

The random appearance and disappearance of epitopes in the major

envelope

glycoprotein

convalescent

and

the pattern

sera suggest

that

the

of neutralization

neutralization

observed

antigenic

with

sites

are

altered during persistent infection.
Tryptic peptide mapping

of gp90 and gp45 components of four virus

isolates (A /l-A /4 )

recovered from sequential episodes separated by as

little as 4 weeks

showed several peptide map additions and deletions

occurring between each isolate and its predecessor.

Our data are in

agreement with results of previous analyses of EIAV isolates and further
indicate that each febrile episode is caused by a distinct virus population
(22, 31).
peptide

Cross-neutralization assays, Western blotting with MAbs and
mapping

of EIAV

isolates

indicate

classify the variants into different groups.

that

each procedure

The maps generated for these

virus isolates were different from those previously reported for
isolates (22, 31).
glycopeptide

and

parallel

Previous studies have shown alterations in the peptide,
oligonucleotide maps of

sequential febrile episodes (26, 28, 31).
that isolates

may

with altered

isolates

recovered

during

More recently we have shown

immunoreactivity patterns, peptide, glycopeptide

or oligonucleotide maps have numerous clustered base substitutions in the
region coding

for the

outer envelope glycoprotein indicating that the

observed antigenic and structural variations have a genetic basis (28).
Antigenic variation in this virus can
appearance of random point

therefore be explained by the

mutations in the envelope gene.

Mutations

y
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affecting

amino

acid

residues

sites

which

are

crucial

or

glycoproteins

can

alter the

that
in

either form neutralization

the

tertiary

folding

antigenicity of the

protein

unreactive with existing protective immune factors.
of

glycosylation

patterns

may

alter

the

of

the
and

antigenic
envelope
render

it

Moreover, alteration

antigenicity

of

the

viral

glycoproteins allowing progeny virus to infect cells in the presence of
immune

factors

specific

for

parental

virus.

The

observation

that

cessation of recurrent febrile episodes was associated with presence of
neutralizing

antibodies

with

broad specificity

suggests

stimulations

of the immune system with several

that

multiple

strainsof EIAV may

generate the necessary immune factors important in the control of virus
replication.
control

the

Although the nature of these immune factors that eventually
cycles

of virus

replication

have

not yet

been

identified,

results lead us to suggest that immunogens derived from several strains
or serotypes of EIAV may be needed to confer protection.
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Fig. 1:

Clinical histories of Shetland ponies experimentally infected with
EIAV.

All

sustained

rectal

temperature

recordings

(dashed line) were considered febrile episodes.

39.5°C

The infectivity

titers in FEK cells of plasma obtained during the febrile periods
are shown as log10 TCID50/m l (vertical bars).

Virus isolates

recovered from the respective febrile episodes are shown, e.g.
A /1 to A/4, etc. (A) pony F135, (B) pony P135 and (C) pony
P130.
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Fig. 2:

Western blot

reactivity patterns of convalescent sera

persistent infections.
protein

specificity

during

Representative data for the patterns of
of

serum

antibody

are

presented.

Pre

inoculation serum at 1:50 dilution against isolate A /1 (panel A).
Serum from pony A on 35 DPI (1:50) (panel B) and 203 DPI
(1:100) (panel C), respectively and
(panel D).

EIA reference serum (1:100)

Viruses A/1, A /4 and prototype EIAV are in lanes 1,

2 and 3 of panels B-D, respectively.

74

4’ '’HP
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Fig. 3:

Western blot reactivity patterns of sera from naturally infected
horses.

The protein specificities of four serum samples were

tested at 1:50 dilution.

Normal horse serum is tested against

prototype EIAV in lane 0.

Sera from four naturally infected

horses are tested in lanes 1-4 against prototype EIAV (panel A)
and isolates A /1 (panel B) and A /4 (panel C), respectively.

9L
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Fig. 4.

Tryptic peptide maps of 125I-gp90 (row A) and 125I-gp45 (row B)
isolated from EIAV strains A/1, A /2, A /3 and A /4.

Peptide

additions (Arrows) and deletions (circles) indicate peptide map
differences

for

each

isolate

when

compared

with

that

of

immediate predecessor, i.e. A /2 is compared with A /1, A /3 with
A /2 etc.

t

<

CO
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Table 1: IgG levels to EIAV glycoproteins and major core protein present
in early (35 DPI) and late (203 DPI) sera by Western blot.

Viral

Percentage

protein

in virion*

Early serum

Late serum

gp90

6.0

3.3a

4.2

gp45

3.0

2.0

3.7

p26

45.0

3.3

4.2

LEVELS

OF

IgG

adapted from Parekh et al (25).
a

Log10 of the reciprocal of highest serum dilution positive for specific
IgG binding.
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Table 2: The protein specificities of MAbs to isolate A /1

and their

reactivity with EIAV isolates in Western blots.

VIRUS

VIRAL
MAba

PROTEIN

ISOLATES

A/1 A/2 A/3 A/4 B /l B/2 C/1 Pb

Fl-120

gp90

+

+

+

+

+

+

+

+

F I-123

gp90

+

+

+

+

+

+

+

+

Fl-102

gp45

+

+

+

+

+

+

+

+

Fl-106

gp45

+

+

+

+

+

+

+

+

Fl-110

gp45

+

+

+

+

+

+

+

+

a

supernatants from hybridoma cell cultures were used at 1:4 dilutions.

b

prototype cell adapted strain of EIAV.
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Table

3:

Immunoblot patterns

of gp90- and

gp45-specific MAbs with

polypeptides of seven EIAV isolates including prototype EIAV

(P).

ISOLATES

VIRUS
P

A/1 A/2 A/3 A/4 B /l B /2

C/1

90-A

+

+

+

+

+

+

+

+

90-B

+

-

+

+

-

+

+

+

90-C

+

+

+

+

-

+

-

+

90-D

+

+

+

+

-

+

-

+

90-E

+

90-F

+

-

+

+

-

+

-

+

45-A

+

+

+

+

+

+

+

+

45-B

+

-

+

+

+

+

+

+

EPITOPES3

a - epitopes in gp90 and gp45 (11)
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Table 4.

Neutralization of EIAV isolates by sera collected from pony A
on different days post-inoculation (DPI).

SERUM

COLLECTION DAY

EIAV- ISOLATE

35*

67

90

203

279

A /1 (16a)

1.5b

3.5

3.5

3.0

3.5

A /2 (46a)

1.5

3.0

3.0

2.0

2.0

A /3 (75a)

1.5

1.5

2.5

2.5

2.0

A /4 (107a)

1.0

1.0

1.5

2.5

2.5

DPI serum collected
a

DPI virus isolated

b

Logio neutralization index (1.7 positive)
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Table 5.

Neutralization of EIAV isolates by serum collected from pony C
that had only one clinical episode of EIA.

SERUM COLLECTION DAY
EIAV PASSAGE

VIRUS ISOLATE

35a

PO*

Prototype

1.5

3.0

P2

P2-1

1.0

3.5

P2-6

1.0

3.5

A /1

1.5b

3.0

A /2

1.5

2.0

A /3

1.5

2.0

A /4

1.0

1.5

B /l

1.5

2.5

B /2

1.5

2.0

C/1

1.0

3.5

P3

EIAV passage in Shetland ponies
a

DPI serum collected

b

Log10 neutralization index (1.7 positive)
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CHAPTER THREE

IN VITRO ISOLATION OF A NEUTRALIZATION ESCAPE MUTANT OF
EQUINE INFECTIOUS ANEMIA VIRUS (EIAV).

SUMMARY
An equine infectious anemia virus isolate (A /1) from the plasma of
a

pony

with

propagated

in

clinical
fetal

signs
equine

of

kidney

neutralizing convalescent serum.
isolated

which

equine
cell

infectious
cultures

anemia

was

in

presence

the

serially
of

After 13 passages, an escape mutant

(A /IE )

was

resisted

neutralization

serum.

Resistance to neutralization of A /IE was associated with loss of

epitope(s) in the major envelope glycoprotein, gp90.

by the

homologous

Our data confirmed

that antigenic variation is an important mechanism for the persistence of
this virus in the presence of neutralizing serum.
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INTRODUCTION
Lentiviruses of man and animals cause persistent infections in their
respective hosts.
(EIAV),

causes

The equine lentivirus, equine infectious anemia virus
a

persistent infection often

characterized

episodes of acute illness marked by high fever (2).
their

hosts

as

integrated

proviruses,

by recurrent

Besides persisting in

lentiviruses

may

persist

immunologically responsive hosts by undergoing antigenic variation.

in
The

occurrence of genomic and antigenic variation in EIAV during persistent
infections in horses has been documented using a variety of serological
and biochemical assays (3, 6, 8, 9, 10, 11).

Analysis of virus isolates

recovered from sequential febrile episodes with a panel of monoclonal
antibodies (MAbs) has documented the presence of common and variable
epitopes
Nucleotide
lentivirus

in

the

major

sequence
genome

envelope

data

has

during

glycoprotein

of

EIAV,

gp90

revealed a high mutation rate

persistent

infections

(10).

It

is

(3).

of this
generally

thought that neutralizing antibodies aid in the selection of new antigenic
virus

variants

during

persistent

infections.

In

infections with

EIAV,

serologically distinct variants emerge possibly through immune selection
pressure operating on random viral genome mutations.

To assess the

possible role of neutralizing antibody in the emergence of new virus vari
ants,

we

generated

a

neutralization

demonstrated that resistance

to

associated with

least

glycoprotein, gp90.

loss

of at

escape

neutralization
one

epitope

mutant
by

of

immune

in the

EIAV

and

serum was

major envelope
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To generate a neutralization escape mutant, a third passage isolate of
EIAV (A /1) was recovered by end-point dilution of plasma from pony A
during the first febrile episode in fetal equine kidney (FEK) cells (11).
This isolate was serially propagated in FEK cells in the presence of
homologous serum.

As a plaque assay does not exist for this virus, the

end-point dilution method

was used to recover the predominant virus

population present in the plasma.

The virus (A/1) and the homologous

serum used in this study were collected from pony A on 16 and 203 days
post-inoculation (DPI) respectively (11).
neutralization index of 3.5

The homologous serum had a

against isolate A/1.

The

conditions for the

propagation of FEK cells have previously been described (7).
study,

the

FEK

cells

(grown

in

25

cm2 tissue

culture

In this

flasks)

were

inoculated with A /1 at a multiplicity of infection of 0.01 and incubated at
37°C for 1 h.

After virus adsorption, cell cultures were rinsed with

warm phosphate buffered saline (PBS, pH 7.2) and 5 ml of maintenance
medium (MEM + 3% fetal calf serum) were added.

After 72 h, heat

inactivated (56°C, 1 h) homologous serum was added (final concentration,
10%) and incubation at 37°C was continued for 3 weeks.

Clarified super

natant medium obtained after 3 weeks was used as inoculum for the serial
passage of A /1 in FEK cell cultures in the presence of homologous serum.
During

the

subsequent

passages,

onto FEK cell monolayers

virus-serum

mixtures

and maintenance medium

were

containing immune

serum was added after virus adsorption without any rinsing.
manner

analogous to

the

inoculated

Thus, in a

conditions that exist in persistently

infected

horses, the homologous serum was maintained in the cultures at all times
during the subsequent passages of A/1.

The A /1 isolate of EIAV was
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propagated in the presence of homologous serum for a total of 13 pas
sages.

The ability of the homologous serum to neutralize A /1 at different

levels of passage was tested in the alpha method of virus neutralization.
During the
incubated
- FEK

final passage in the

with an equal

cells.

selecting serum,

the virus was pre

volume of undiluted serum and inoculated onto

The recovered virus was "cloned" by end-point

dilution in

FEK cell cultures and designated as A /IE to denote a neutralization esc
ape mutant derived from isolate A/1.

The serological relatedness between

A /1 and A /IE was assessed by virus neutralization using homologous and
heterologous sera.
pony

The heterologous serum was collected on 438 DPI from

C which had received the same inoculum as pony A

details for virus neutralization are

described

elsewhere

(11).

(11).

The
Briefly,

serial 10-fold dilutions of each virus were mixed with a standard dilution
(1:4 in MEM) of heat inactivated (56°C, 1 h) serum.
mixtures

were incubated

infectious

virus by inoculating duplicate FEK

aliquots.

Controls consisting

were

at 37°C for

included for each test.

described (1).

1 h and

The virus-serum

assayed

for

residual

cell monolayers with 1 ml

of mixtures of virus dilutions

with MEM

Virus antigens were assayed as previously

The neutralization index for each serum was calculated as

the difference in virus titre between samples without serum and that of
the virus-serum mixture.

A logi0 neutralization index (LNI) of

1.7 was

considered positive.
The

ability

of virus

isolate

A/1

to

resist

neutralization

homologous serum was monitored by virus neutralization assay.
of virus

A /1 after

sixserial

passages

(A /1/6)

in

the

by

the

The LNI

presence

of

homologous serum was 1.5 lower than that observed for the parent virus
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(Table

1).

A

difference of 1.5 LNI was observed in virus isolates

recovered from sequential febrile episodes (11) implying that after six
serial passages A /1 in the presence of neutralizing antibodies a significant
antigenic alteration had occurred.

The virus was further propagated until

by 13 passages it completely resisted neutralization by homologous serum
and had a modified neutralization pattern by heterologous serum (Table
1).

These data indicated that after multiple passages of EIAV in the

presence of immune serum the virus had altered antigenic sites which led
to inability of homologous serum to neutralize.
acquired
either

neutralization

that

the

antigenic

Partial recognition of the

sites by heterologous

specificity of the selecting serum

serum

suggested

may determine

the

serological divergence of the new virus strain or that more than one site
is involved in virus neutralization.

The. failure of the selecting serum to

neutralize the new virus variant (A / IE) is analogous to what happens in
chronic ELA when virus variants emerge in the presence of antibodies
with

type-specific

neutralizing

activity

and

antibodies

reacting

group-specific determinants of the envelope glycoproteins (11).

with

New virus

populations could emerge during persistent infections in horses as a result
of high replicase errors associated with the reverse transcription of virus
genome and immune selection pressure.

Our data documented for the

first time that antibody-mediated immune selection pressure can operate
in the emergence of new serological variants of EIAV.

The process was

gradual and required multiple passages in the selecting serum.

During

chronic EIA, virus isolates are serologically different even when recovered
during sequential disease episodes separated by as little as four weeks
(11).

The rapid evolution of EIAV during persistent infection in horses
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may be due to the lytic infection of highly permissive cells (i.e., monocy
tes and macrophages) a process that would lead to multiple cycles of
virus replication amplifying the replicase errors associated with reverse
transcription.

Immune selection pressure then operates on a markedly

heterogeneous virus population allowing virus variants to emerge rapidly.
In contrast, the replication of EIAV in cultured equine fibroblasts is nonlytic and

less permissive.

During persistent

infection

in these

cells,

resistance to homologous superinfection may be mediated by viral receptor
down-regulation as a
envelope

proteins.

result of the complexing of receptor with viral
This

could

involving reverse transcription.

limit

the

cycles

of virus

replication

Such a process would limit the rate of

viral genome change occurring in persistently infected cells.

Antibody

selection pressure is then likely to operate on less heterogeneous virus
populations and new virus variants would take longer to appear in vitro
than in vivo.
The emergence of a serological variant of EIAV after several passages
of an end-point diluted virus in the presence of neutralizing serum su
ggested

that

the

variants

recovered

present in the inoculum virus.

during

chronic

EIA

are

not

all

Our data indicated and confirmed that

antigenic variation in the equine lentivirus is one of the mechanisms by
which this virus can persist in the presence of immune serum.

The

alteration of neutralization antigenic sites of EIAV in this variant did not
involve

the

functionally

equine

fibroblasts.

conserved

This

domain which

suggested

that

at

allows
least

replication

this

in

functionally

conserved domain of EIAV is not the target for neutralization of virus
infectivity.

Moreover, immunoblot analysis of A/1 and A /IE with the
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selecting serum (Fig
recognizing

1) were similar further indicating that antibodies

conserved

antigenic

domains

in

gp90

and

gp45

are

not

involved in virus neutralization.
To further characterize the neutralization escape mutant, A /IE was
propagated in FEK cell cultures and purified using previously described
methods (5).

The viral proteins were separated under reducing conditions

on 7.5 to 20% gradient gels by SDS-polyacrlyamide gel electrophoresis and
transferred to nitrocellulose membranes as described elsewhere (11).

All

incubations with antibody or with Tris-buffered saline (lOmM Tris-HCl,
0.9% NaCl, pH 7.4) (TBS) were at 37°C with agitation.

The nitrocellulose

strips were blocked for non-specific binding of antibody with 5% non-fat
dry milk (4) in TBS for 2 h and incubated for 2 h at 37°C with monoclo
nal antibodies (MAbs) at 1:20 dilution or equine serum (203 DPI serum) at
1:100 dilution

in TBS containing 1% non-fat dry milk-

After incubation

with MAbs or serum, the strips were washed twice (10 min/wash) in TBS
containing 0.05% Tween 20 (SIGMA) and incubated for 1 h with peroxidase
labeled goat anti-mouse immunoglobulins (CAPPEL, COOPER BIOMEDICAL,
INC., MALVERN, PA) rabbit anti-equine IgG (SIGMA Chemicals, St Louis,
MO.)

diluted at

respectively.

The

1:1000
strips

in

TBS containing

were

processed for

1%
color

non-fat dry
with

milk,

4-chloro-l-

naphthol in methanol (Bio-Rad, Richmond, CA).
The production and characterization of MAbs 86, 82, and 115 has
previously been described (3).
exists in all the
respectively (Fig 2).

EIAV

MAb 86 recognizes an epitope (90-A) that

isolates tested

(3) including A /1

and A /IE ,

Our results indicated that during serial propagation

of A /1 in homologous serum, the epitopes recognized by MAbs 82 and 115
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were apparently altered and could not be detected in A /IE by Western
blot.

Although MAbs 82 and 115 failed to neutralize A /1, our data

demonstrated

that

resistance

to

neutralization

by

equine

convalescent

serum was associated with loss of epitopes recognized by these MAbs.
All three MAbs used in this study reacted with the gp90 of a virus
isolate A /2 the in vivo homologue of isolate A /IE ) that was recovered
from pony A four weeks after the isolation of A /1 (11), indicating that
new virus variants emerged from the predominant virus population in a
random fashion.

The consideration that A /IE is the homologue of A /2

assumes that, in vivo, virus variants evolve from the predominant virus
population i.e. A/1.

Previous data has shown that gp90 is a target for

neutralizing MAbs and during persistent infections rearrangement of epit
opes occur in gp90 with minor or no alterations in gp45 (11).

Moreover,

analyses of sequential and parallel isolates of EIAV recovered from ponies
infected with the same virus have shown that the isolates are structurally
and

genetically

different

(9,

10,

12

).

In

contrast,

antigenic

and

structural alterations in gp90 and gp45 have not been observed during
continued propagation of EIAV in cell cultures in the absence of immune
serum

(6).

The

of

EIAV

variants
however,

appearance
before

indicates

that

the

of structurally
development

selection

of

and
of

virus

antigenically

neutralizing
variants

distinct

antibodies,

also

involves

mechanisms other than by neutralizing antibodies (11).
Our

data confirmed

mutable virus.

previous observations that

EIAV

is a highly

During persistent infection in horses, antibody selection

pressure could result in the emergence of novel variants that cause the
recurrent

febrile

episodes

associated

with

chronic

EIA

in

a

manner
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analogous to our in vitro model.

The generation of a virus variant from

end-point diluted virus indicates that the viruses that are recovered from
persistently infected horses may evolve from a single virus population by
random mutations in the viral envelope gene.
was enhanced by immune selection pressure.
this in vitro isolate will be necessary.

Selection of this mutant
Further characterization of

Preliminary data indicate that the

in vitro isolate maintained its virulence and infectivity for ponies as signs
of clinical

EIA

unpublished
isolates

were

results).

may help

observed

Nucleotide
identify

within

10 days

sequence

sequences

of

analysis

that

are

inoculation

of

A /IE

important

in

(Issel,

and

A/1

antibody-

mediated immune selection pressure either alone or with other immune
factors

present

generation

of

in

infected

animals,

respectively.

virus

variants

in

using

vitro

either

Moreover,
defined

sera

the
or

monoclonal antibodies and their subsequent genetic analyses will help to
identify

sequences

Identification

that

of such

frequently

sequences

effective immunogens for EIA.

change

may be

during

important

virus
in

the

replication.
design

of

The antigenic variation documented for

EIAV during persistent infection in horses and in cell culture in the
presence of neutralizing antibodies may be a general mechanism for the
persistence of lentiviruses of man and animals in immunoresponsive hosts.
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Fig 1:

Western blot analysis of the neutralization escape mutant A /IE
and the parent virus A /1

with the selecting immune serum.

Reference EIA negative equine serum is tested in lane 1 against
isolate A /IE at 1:50 dilution.

Isolates A /IE and A /1 are tested

in lanes 2 and 3, respectively with 203 DPI serum at 1: 50
dilution.
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Fig. 2:

Western blot analysis of EIAV isolates A /1 (parent) and A /IE
(neutralization escape mutant) with a panel of MAbs reactive
with the major envelope glycoprotein, gp90.

MAbs 86 (lane a),

82 (lane b) and 115 (lane c) were used at 1:10, respectively.
Virus A /1
(panel B).

(panel A) and neutralization escape mutant A /IE
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Table 1.

Neutralization of EIAV isolates A /1 and A /IE by homologous and
heterologous equine convalescent sera.

VIRUS
A/1

A/1/6*

A/1E+

Homologous

3.5++

2.0

0.7

Heterologous

3.0

ND

2.0

SERUM

A /1 virus after 6 passages in the presence of homologous serum.
+

A /IE isolated after 13 passages of A /1 in the presence of homologous
serum.

++ Log10 neutralization index ( 1.7 positive).
ND - not done.

CHAPTER FOUR

APPLICATION OF THE SINGLE-STEP IMMUNOBLOT (SIB) TEST IN
DIAGNOSIS OF EQUINE INFECTIOUS ANEMIA AND DETECTION OF
ANTIGENS OF EIAV.

SUMMARY
A simple and rapid single-step immunoblot (SIB) assay for antibodies
to

specific

antigens

of

equine

infectious

anemia

virus

(EIAV)

compared with AGID, competition-ELISA and Western blot.

was

A high

correlation was observed between these serologic tests in samples with
weak positive or positive AGID reactions.

Samples with equivocal AGID

reactions (8%) tested positive for anti-EIAV antibodies in C-ELISA and
Western blots, respectively.

These samples could be positively identified

with the SIB test using a combination of viral gp90 and p26.

In the SIB

test, sera were incubated with viral antigens in the presence of "SIB
reagent", a

protein A-colloidalgold suspension containing a blocker for

non-specific binding of antibody.

Results to detect equine IgG in Western

blots were comparable using peroxidase labeled rabbit anti-equine IgG or
SIB reagent.

The advantages of SIB include speed, low cost and lack of

background problems

often

dilutions are used.

The SIB test was found to be applicable for

rapid

EIAV p26 antigen in fluids from infected cell cultures.

The

detection of

seen

in

Western

blots

when

low

serum

test has potential for wide application in diagnosis of human and animal
viral infections.
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INTRODUCTION
Equine infectious anemia virus (EIAV) causes a persistent infection in
horses that is often characterized by recurrent febrile episodes (3, 5).
Horses infected with EIAV produce antibodies to most if not all the viral
proteins.

Antibodies to EIAV antigens can be detected in the serum of

infected horses in a number of serological assays including the agar gel
immunodiffusion (AGID) test (4), enzyme linked immunosorbent assay (14)
and Western blotting (6).

As horses infected with EIAV remain viremic

for life and pose a threat to uninfected horses, their rapid and accurate
identification is imperative in the control of this disease.
Although
infection,

AGID

the

test

seropositive horses (6).

test seropositivity
lacks the

correlates

sensitivity

to

very

identify

highly
all

with

infected

In such cases, other testing procedures including

competition-ELISA (C-ELISA) and Western immunoblot have proven more
sensitive than the AGID test (6).

The rapid and accurate diagnosis of

virus infections is an important facet in disease control programs.
need

exists

for

continued

search

of

diagnostic

sensitive, specific, rapid and easy to use.
rapid,

accurate

and

easy to

perform

procedures

that

A
are

In this study, the use of a
single-step immunoblot

(SIB)

procedure for the detection of EIAV antibodies was evaluated.

The assay

is based

solid-phase

on

the

binding

of specific

serum

antibodies

adsorbed viral antigens and detection by a protein A gold

to

probe.

The

test has enormous applicability as antibodies to many antigens/infectious
agents can be simultaneously detected.
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MATERIALS AND METHODS

Virus

antigens:

The

cell culture

adapted

Wyoming strain

of EIAV

(prototype virus) (10) was produced in fetal equine kidney cell cultures
and purified using previously described procedures (11).

The EIAV major

envelope glycoprotein gp90 and the major core protein p26 were purified
from density gradient purified virus in a reverse-phase high performance
liquid

chromatography

(HPLC)

column

as

described

elsewhere

(8).

Recombinant p26 covering the Pvu/Dra site in the gag gene was cloned
and expressed in E. coh as a fusion protein containing half of pl5, entire
p26, 8 residues of p l l and 38 amino acids of trp L (Payne, unpublished
results).
test

The recombinant antigen was solubilized in 8M urea.

kits were

commercially

obtained

from

Pittman-Moore,

The AGID
Washington

Crossing, NJ and C-ELISA test kits were kindly supplied by Tech America
Corp. Kansas City, MO.

Serum samples:

The routine diagnosis of EIA is based on the detection

of anti-virus antibodies in AGID or C-ELISA test.

Equine sera were

collected from a variety of geographical areas in the United States and
tested for anti-virus antibody in the AGID test.

A total of 115 sera

were tested in C-ELISA, Western blots and the SIB test.

Five of these

sera were from horses previously known to be AGID test positive and
which

subsequently

became

equivocal

or

negative

AGID

reactors.

International reference serum (IRS) for EIA was obtained through Dr. Jim
Pearson (USDA Veterinary Services Laboratory, Ames Iowa) and was used
in all the four serologic tests for comparison.

EIA positive serum (Lady)
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with a strong AGID reaction, sera with weak AGID reactions and pooled
EIA negative serum were included as controls.

Rabbit anti-p26 serum was

prepared by immunizing rabbits with HPLC purified EIAV p26.

AGID test and C-ELISA:
and

The AGID test was conducted using the approved

protocols

(12)

was

read

after 24 h

according to

manufucturer’s

criteria.

Samples which caused a deviation of the reference positive

serum precipitation line similar to that observed with IRS, but did not
form a line in common with reference positive serum, were judged as
weak positive reactions.

Samples which led to a disagreement in the

interpretation of the reaction by three trained individuals were regarded
as equivocal.

Those samples which formed a line of precipitation in

common with the reference line were interpreted as positive.
ELISA test was

performed according

to the

(TechAmerica Corp., Kansas City, MO).

The C-

manufacturer’s procedures

Samples which visually gave an

equal or lower intensity of color than the reference positive sample were
considered positive.

Protein A-gold conjugation:

Colloidal gold particles of uniform size (15

or 30 nm) were produced by reduction of 0.01% tetrachlorouric acid with
1% sodium citrate according to previously described methods (15).

The pH

of the colloidal gold sol was adjusted to approximately 7.0 with 0.01M
K2C 0 3 and

the

optimum amount of

Staphylococcus aureus protein A

(SIGMA Chemicals, St. Louis, MO) in

0.05M Tris buffer (pH 7.4) added.

After testing the stability of protein A-gold with
precipitate forms

upon addition of

10% NaCl (a blue

NaCl when the amount of protein
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present

is

insufficient

to

protect

the

colloidal gold

from

salt-induced

flocculation), Tris buffer containing 0.1% polyethylene glycol 20M (PEG
20M) was added.

The protein A gold solution in 0.05M Tris buffer (pH

7.4) containing 2.5-4% non-fat dry milk (Carnation) as a blocker was used
as the detecting reagent.

The detecting reagent (subsequently referred to

as the SIB reagent) could be stored at 4°C for up to 1 year.

Determination of optimum

amount of antigen and serum dilution for

single-step immunoblot (SIB):

Density

gradient

purified

treated with 4M KSCN (v/v 1:10) for 15 minutes at 37°C.

virus

was

The disrupted

virus, p26, recombinant p26 and gp90 were diluted in Tris-HCl (0.05M, pH
7.4) to

include

antigen

dilutions

a concentration range of 200ng/il to
were

(nitrocellulose membrane,

spotted

in

ill

aliquots

0.45um, Schleicher and

on

a

1.5ng/il.

The

support

matrix

Schuell, Keene, NH),

incubated at 56°C for 20 minutes to dry and fix antigen, and placed into
test-tubes containing the SIB reagent.

Each panel of antigen dilutions

was tested against sera with negative, strong or weak AGID reactions for
virus specific antibodies, respectively, at three final dilutions: 1:10, 1:100
and 1:1000.
the

SIB

The appropriate volume of each serum was added directly to
reagent

containing

the

specific

antigen(s).

The

antigen

preparations were also incubated with the SIB reagent but without serum
as control for non-specific binding of colloidal gold.
incubated at room temperature with agitation.

The tests were

The development of a

colored spot at the site of antigen indicated the presence of specific
antibody.

As rabbit IgG binds with protein A with high affinity and the

SIB reactions occur faster, rabbit anti-p26 serum was used for assessing
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activity of the SIB reagent.

SIB test for EIAV antibody:

For detection of antibodies to EIAV in the

sera of test horses, HPLC-p26 (40ng/il) in Tris-HCl buffer (0.05M, pH 7.4)
was spotted on the support matrix as described above and incubated in
the SIB reagent containing a 1:100 final dilution of test serum.

Sera with

weak or equivocal AGID or C-ELISA reactions were tested in SIB using a
panel of viral p26, recombinant p26 and gp90 blotted on the same strip of
nitrocellulose membrane.

Western blot:

EIAV

proteins

were

separated

on

discontinuous

(4%

stacking gel), 7.5 to 20% gradient gels by SDS-PAGE under reducing
conditions

(9).

nitrocellulose

The

membranes

separated
(0.45im,

previously described methods

(2).

viral

proteins

were

Schleicher and

electroblotted

Schuell)

to

according to

Nitrocellulose membranes containing

separated EIAV proteins were incubated with 5% non-fat dry milk (7) in
Tris buffered saline (TBS) (lOmM Tris, 0.9% NaCl, pH 7.4) for 2 h at
37°C.

Serum samples (n=78) were tested against prototype EIAV and two

antigenically different strains of EIAV (isolates A /1 and A /4) isolated
from a pony during recurrent febrile episodes.

All serum samples were

diluted in TBS containing 1% non-fat diy milk and incubations and washes
were done at 37°C with agitation.

The membranes were then incubated 2

h with test sera (1:50), washed twice (10 min/wash) in TBS containing
0.05% Tween 20 (SIGMA) and incubated for 1 h with peroxidase labeled
rabbit-anti horse IgG (1:3000; MILES-YEDA LTD, ISRAEL).

After two

washes (10 min in TBS/0.05% Tween-20 and 10 min in TBS) bound
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antibody was detected with 4-chloro-l-naphthol (Bio-Rad, Richmond, CA)
in TBS.
which

Specific viral antibodies were also detected in the SIB test in

case

the

proteins were

nitrocellulose

membranes

incubated for 2-4 h in

containing

separated

EIAV

SIB reagent containing 5%

(w/v)

non-fat dry milk and 1:100 of the test serum.

Detection of EIAV antigen in the SIB test:

Supernatant

media

from

infected and uninfected cell cultures were treated with 40% polyethylene
glycol

(PEG)

described

and

(1). For

assayed for EIAV
detection

of

antigen essentially as previously

EIAV

antigens

in

the

SIB

test,

supernatant media from known infected and uninfected cell cultures were
clarified at 1,000 x g, treated with 40% PEG for 1 h and precipitated by
centrifugation

at 1,500 x g for 1 h.The precipitated materials

were

resuspended in 50il of borate buffer (0.05M, pH 8.6), 8M urea, 5% SDS or
4M KSCN.

An equal volume of di-ethyl ether was added to the borate

buffer mixture.

For disruption of virus, the mixtures were incubated with

these reagents at 37°C for 15 minutes.

Aliquots of each sample (lil)

were then spotted on nitrocellulose membrane and incubated at 56°C for
20 minutes for protein binding.

The membranes containing test antigens

and 40ng of p26 (positive antigen control) were incubated in SIB reagent
containing 1:100 of rabbit anti-p26 serum.
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RESULTS

Optimum conditions for SIB test.
The

optimum

concentration

for

each

antigen

preparation

was

determined in a checker-board titration of antigen and EIA positive or
negative sera.
against

sera

An antigen concentration which gave positive reactions
with

weak

AGID

reactions

and

negative

reactions

with

reference EIA negative serum was selected as optimum for the test.
Detergent disrupted EIAV showed low specificity for anti-virus antibody
as some sera negative in AGID and Western blot tested positive.

The

concentrations

high

of

HPLC-p26

and

recombinant

p26

that

gave

specificity and strong intensity of color reactions were 40ng and 200ng,
respectively (Table 1).

For sera that tested strongly in AGID, as little as

3ng of viral p26 and 12ng of recombinant p26, respectively, could be used
(Table 1).

Purified gp90 was used at 50ng for sera with positive AGID

reactions and lOOng for sera with weak positive AGID reactions.

The

kinetics of the SIB test were different for equine and rabbit sera and
were influenced by the serum dilution and the relative amounts of EIAV
specific antibodies in each serum (Table 2).

The influence of species and

serum dilution on the kinetics of the reaction was greatest for the equine
serum probably as a result of the low affinity of protein A for equine
IgG compared with that of rabbit.

From the kinetics data, an optimum

serum dilution of 1:100 was selected for equine sera.
dilutions

greater

than

1:100 could

be

used

For rabbit serum,

effectively.

With

these

standards, the SIB test using protein A-colloidal gold conjugate was used
to detect antibodies to EIAV in equine serum with results evident within
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4 h in all but sera with weakest positive AGID reactions.

Detection of anti-EIAV antibodies in AGID, C-ELISA and
Western blot.
All serum samples were initially tested by AGID and C-ELISA.

The

samples were grouped as negative, equivocal, weak positive or positive
according to their AGID results (Table 3).

All the samples with equivocal

AGID reactions gave positive reactions in C-ELISA and had reactivity to
EIAV gp90 in Western blots (Fig. lanes 3, 4, 5, 7, 8 and 9).
six samples also had reactivity to EIAV gp45 and p26.

Five of the

It was necessary

to dilute serum samples fifty fold to eliminate background staining in
Western blot.

Two samples (10165 and 10126) from a horse (mare 4) with

a history of AGID test positive results were AGID test negative but
positive in Western blot at the time of this study (Fig 1, lanes 3 & 9).
Sample 10165 was also positive in C-ELISA and had comparable activity to
that of IRS in Western blot (Fig. 1, lanes 2 & 3).

All samples with

equivocal AGID reactions and 2 samples with negative AGID reactions had
high activity to gp90 in Western blot.
There was complete agreement in AGID, C-ELISA and Western blot
results for groups of samples with weak AGID results (Table 1).

All 63

samples had detectable reactions against gp90, gp45 and p26 of prototype
EIAV, isolate A /1 and isolate A/4, respectively.

Strong activity to gp90

and gp45 and weak activity to p26 was observed at the
dilution used.

1:50 serum

Differential reactivity to gp45 of the three virus strains

was observed with a few of the serum samples with positive AGID results
(Fig. 1, lanes 10-12).
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The reactivity of

equine sera with EIAV proteins separated on SDS-

PAGE and blotted to nitrocellulose membranes was also detected in the
SIB test.

With EIA positive sera, intense color developed within 2-4 h

(Fig. 2).

Western blots developed using the SIB reagent or peroxidase

labeled rabbit anti-equine IgG gave identical results.

The reference EIA

negative serum had no reactivity and at the 1:100 serum dilution used
there was no background staining with the SIB reagent.

The colloidal

gold gave stable reactions while membranes processed with the peroxidase
system faded with storage.

SIB for the diagnosis of EIA.
Analysis of 115 sera in the SIB test showed high correlation between
results in the SIB test using HPLC purified p26 (40ng) and the USD A
approved diagnostic tests for EIA including the AGID and C-ELISA tests
(Table 4).

As all the

sera with equivocal AGID

results would be

considered as EIA test-negative by most trained personnel, the six serum
samples with equivocal AGID reactions were recorded as negative for
comparison (Table 4).

There was 100% correlation for all sera with AGID

reactions equal to or stronger than that of the International Reference
Serum (Table 4).

There was also 100% correlation between C-ELISA and

the SIB test for six sera with equivocal AGID reactions including AGID
test-negative samples from horses with a history of AGID test positive
results.

Two serum samples negative in AGID and C-ELISA, respectively,

tested positive in the SIB test when HPLC purified p26 was used (Table
4).

These two samples were also negative in Western blots.

The two

samples gave no reactions when gp90 and recombinant p26 were used in
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the SIB test.

EIA positive results were indicated by reactivity with gp90

alone or in combination with p26 (Fig. 3).
with

equivocal

AGID

reactions

tested

On the other hand, some sera
positive

only

with

recombinant p26 (Fig. 4) and required longer incubation times.

gp90

and

The same

sera (Flicker and FLA 253) were shown to have antibodies to gp90 and
p26 in Western blots (Fig. 1, lanes 4 and 5).

Detection of EIAV antigens.
The presence of EIAV in infected cell cultures was assayed in the
SIB test using rabbit serum to purified

EIAV p26.

Detection of virus

antigens in supernatant medium of FEK cell cultures was determined in
AGID and the SIB test.

The SIB test could yield results within 4 h in

contrast to the 48 h usually required for antigen detection by AGID.

In

persistently

in

infected

FEK

cell

cultures,

supernatant fluids without any treatments.

EIAV

p26 was

detectable

However, the detection of p26

early during the infection required pretreatment of clarified supernatant
media with
reagents.

PEG

and

disruption of precipitated virus with chaotropic

Treatment of the precipitate with borate buffer, urea and SDS

gave negative

or more variable

results possibly due

to poor

antigen

binding on the support matrix or inadequate release of the major core
protein.

Disruption of precipitated virus with 4M KSCN consistently gave

positive

results

tested.

Supernatants fluids from uninfected cell cultures did not test

when

supernatant

fluids

from

infected

cultures

positive with normal rabbit serum or rabbit anti-p26 serum.

were

A positive

antigen control (40ng of p26) was included in the test to check activity
of the SIB reagent and the rate of the reaction, respectively (Table 5).
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DISCUSSION
EIA is currently diagnosed by detection of anti-EIAV antibodies in
serum of

infected horses in AGID and C-ELISA tests (5, 6).

These

serological tests have been useful in controlling the spread of EIA.

In

certain cases, however, these tests fail to detect infected horses which
appear

to

have

low levels

of anti-EIAV

antibodies

(6).

This

low

sensitivity may result in the erroneous interpretation of the serological
results.

In these instances, Western blot procedures have proved more

sensitive (6).
In this study, several
anti-EIAV antibodies.

serologic tests were evaluated

for detection of

There was excellent agreement between AGID, C-

ELISA, Western blot and the single-step immunoblot in samples with AGID
test reactions

equal in intensity to or stronger than the, international

reference serum.

However, some serum samples may have extremely weak

AGID reactions and be reported as AGID test-negative during routine
testing for EIA.
reactions,

had

Such samples,
antibodies specific

designated as having equivocal AGID
for

EIAV gp90,

gp45

and

p26

as

revealed in Western blots.

Moreover, all the equivocal AGID reactors

were detected in C-ELISA.

These results indicated that the AGID is not

very sensitive for the detection of low levels of virus-specific antibodies.
The Western

blot procedure had the highest sensitivity for

detection of

anti-EIAV antibodies in sera from experimentally or naturally infected
horses.

Most of the activity was to common antigenic determinants in

EIAV gp 90 and gp45; activity to p26 was generally weak and variable.
The useof a rapid single-step immunoblot assay
anti-EIAV

antibodies and EIAV antigens was evaluated.

for

detection of
In this assay,
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specific

antibody

binds

with its

Fab-site

to

antigen

attached

to

nitrocellulose membrane and with its Fc-site to protein A conjugated with
colloidal gold.

This reaction and the blocking of unsaturated sites on the

support matrix occur concurrently.

Analysis of 115 sera in this assay

using

test

EIAV

p26

showed

that the

had

a comparable

level

of

performance to that of USDA approved tests for EIA.

Disrupted purified

virus

cross-reactivity

had

low

specificityprobably

as

a result

of

of

natural equine antibodies with cellular or serum proteins in the virus
preparation.

Because of the high sensitivity of the detecting reagent only

highly purified antigens should be used to avoid non-specific reactions.
Two serum samples negative in AGID, C-ELISA and Western blots gave
positive reactions in the SIB test using HPLC purified p26.
positive"

SIB

reactions

may

be

due

to

either

These "false

non-specific

reactions

possibly due to high amounts of pure p26 used or to the recognition of
determinants

in

the

purified p26

by

retroviruses.

This is deserving of further

antibodies
study.

to other

equine

However, analysis

of

serum samples with gp90 and recombinant EIAV p26 expressed in E. coli
gave the expected results including negative results for the two sera with
"false positive"

SIB results,

indicating

that

these

combination

of viral

antigens should be used for high sensitivity and specificity of the SIB
test.

The results also showed that recombinant p26 expressed in E. coli

maintained
higher

its

quantities

antigenicity

for

ofrecombinant

change with sera that
specificity of this test.

anti-EIAV
p26

antibodies.

required

to

Moreover,
give intense

the
color

had weak reactions in AGID test did not lower the
The reactions of two sera with equivocal AGID

reactions showed reactivity with

gp90 and recombinant p26 indicating that

I ll
sensitivity approaching that of the Western blot could be achieved in the
SIB test.

These results were in agreement with our previous reports

indicating that all horses with a history of AGID test-positivity contained
antibodies to the virus major envelope glycoprotein which reacted with
apparent group-specific determinants (6, 13).

Thus, the use of EIAV

recombinant p26 and gp90 antigens in the SIB test would provide a
sensitive and specific test that is inexpensive, rapid and suitable for any
laboratory or field setting.
The Western blot procedure was shown to be highly sensitive for
diagnosis of EIA in horses with levels of anti-EIAV antibodies that are
below

the

however, is

sensitivity

of

the

AGID

and

C-ELISA.

This

procedure,

expensive and not practical for the routine diagnosis of EIA

and other viral infections.

The SIB procedure is not dependent on

expensive equipment and can detect presence of specific antibodies to a
variety of antigens spotted on the same support matrix.

The combination

of different viral proteins on the same support matrix, e.g., gp90 and p26,
was useful in detecting anti-EIAV antibodies in sera with low levels of
antibodies to either protein.

Use of combinations of purified preparations

that represent the most immunogenic and antigenic proteins of a virus
should

give SIB test high sensitivity and

specificity without the

high

costs of a conventional Western blot.
Production of EIAV in persistently infected cell cultures was easily
monitored in the SIB test using rabbit anti-EIAV p26.

The test had high

specificity for EIAV antigens and detectable antigens were present in lil
of

supernatant

fluids

from

persistently

infected

cell

without pretreatment with PEG and chaotropic reagents.

cultures

with

or

The detection of
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EIAV antigens in the AGID test takes at least 48 h. (1).

In this study,

viral antigens could be detected in the SIB test with anti-p26 serum
within 2-5 h.

The SIB test therefore presents a rapid method for the

detection of anti-EIAV antibodies in serum of horses and EIAV antigens
in the supernatant fluids of infected cell cultures, respectively.
In contrast with other immunoassays, the SIB test did not require
pre-blocking of unsaturated sites in the antigen support matrix, washes,
or second antibody which in most cases needs further processing for
either chromogenic reactions or autoradiography.

Moreover, the test was

easy to interpret as a contrasting color developed at the antigen sites in
the presence of specific antibody.
application

in

the

detection

The test holds great potential for wide

of

antibodies

with

specific

detection of antigen with specific antisera, respectively.

antigen

or

In viruses where

distinct serotypes exist, this test can be of great epidemiological value
especially when serotype specific antigens or synthetic peptides are used.
Use of colloidal gold conjugated with proteins that have high affinity for
the

Fc-portion

increase

the

of

immunoglobulins

sensitivity,

reduce

from

many

the turnaround

species
time

and

spectrum for the use of this assay with sera from different species.

would

greatly

broaden

the
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Table 1.

Sensitivity of SIB test for HPLC purified p26 and recombinant
p26 using EIA positive equine sera and EIA negative reference
serum.

AMOUNT OF ANTIGEN (ng/microliterl
ANTIGEN

AGIDa

p26

rec-p26

a

200

100 50

Sb

+

+

+

W

+

+

+

N

.............................................................

S

+

+

+

w

+

+

.

N

.............................................................

v.

25

12

6

3

+

+

+

+

+

-

+
.

-

+
.

-

.

.

AGID activity for anti-EIAV antibody indicated as strong (S),
weak (W) or negative (N) (see text for

b

sera tested at 1:100 dilution in the SIB reagent.

+

positive for specific antibody after 3 h.
negative for specific antibody after 3 h.

detail),
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Table 2. The kinetics of SIB test for equine and rabbit sera using 40ng of
HPLC purified p26.

SERUM

TIME IN MINUTES

SOURCE

DILUTION

5

15

60

HORSE

1:10

-

-

(S)

1:100

-

1:1000
HORSE
(W)

120

240

-

1+

2+

-

1+

1+

3+

-

-

-

1+

1+

1:10

-

-

-

-

1+

1:100

-

-

-

1+

2+

1:1000

-

-

-

-

-

RABBIT

1:10

1+

2+

3+

4+

4+

(S)

1:100

1+

2+

3+

4+

4+

1:1000

1+

1+

2+

4+

4+

(S)

Reference horse serum or rabbit anti-p26 serum with strong
AGID reaction.

(W)

Positive horse serum with weak AGID reaction.

(-/ +)

negative or positive for specific antibody (number of pluses
indicate intensity).
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Table 3. Correlation of AGID, C-ELISA and Western blot in the detection
of anti-EIAV antibodies in equine sera.

C-ELISA
AGID

Number

reactions

tested

# Positive

WESTERN-BLOT*
# Positive to:
gp90

gp45

p2<

Negative

9

1

2

2

2

Equivocal

6

6

6

5

5

Weak positive

38

38

38

38

38

Positive

25

25

25

25

25

serum samples tested at 1:50 dilution against prototype cell culture
adapted EIAV.
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Table 4. Comparison of AGID, C-ELISA and SIB serologic assays for
detection of anti-ELAV antibodies in equine sera.

AGIDa

Number

C-ELISA!*

SIB£

reactions

Tested

# POS.

# NEG.

#P O S .

# NEG,

Negative

15

7

8

9

6

Positive

100

100

0

100

0

a

Interpretation of AGID explained in text.

b

Sample positive if intensity of color was equal to

or lowerthan that

of the positive reference sample.
c

SIB test using 40ng of HPLC purified p26.
the SIB reagent and the test was scored after 4 h.

Sera were

diluted 1:100

in

120
Table

5.

Detection

of

EIAV

antigens

in

the

supernatant

fluids

of

persistently infected cell cultures.

ANTIGEN TREATMENTS
Cell

Borate

Urea

SDS

KSCN

Cultures

.05M

8M

5%

4M

Infected

-

+

++

++

Uninfected

-

-

-

p26b

NA
NA
+++

NA

a

Clarified supernatant medium was treated with 40% PEG and processed
as described in the text.

b
-o r

HPLC purified p26 (40ng) was included as positive control antigen.
+

indicate

negative

or

positive

results

after

incubating

each

preparation with 1:100 dilution of rabbit anti-p26 serum in the SIB
reagent. The number of pluses indicate color intensity.
NA- not applicable.

121
Fig.

1:

Western blot profiles of selected serum samples against the
prototype cell adapted strain of EIAV are shown in lanes 1-10.
The reactivity of one serum sample against prototype EIAV (lane
10), isolate A /1 (lane 11) and isolate A /4 (lane 12) is included
for comparison.

Serum samples in lanes 1-12 are as follows: (1)

reference ELA-negative horse serum; (2) international reference
serum; (3) 10165; (4) Flicker; (5) FLA 253; (6) mare 51; (7) mare
40; (8) Stallion 6; (9) 10126; and (10-12) FLA 191.
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Western blot analysis of equine sera with the SIB reagent or
peroxidase

labeled

rabbit

anti-equine

IgG.

Virus

specific

antibodies are tested in panel A with the SIB reagent and panel
B with peroxidase labeled rabbit anti-equine IgG, respectively.
Reference EIA negative equine serum is tested in lane 0 and EIA
positive

sera are

respectively.

tested

in lanes

1-2 of panels A

and

B,
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Fig. 3:

Detection of antibodies to EIAV gp90 and p26 in SIB test. Sera
with weak AGID reactions are tested in lanes 1-4 and sera with
strong AGID reactions are tested in lanes 5-8.
negative equine serum is tested in lane 0.

Reference EIA

Each serum is tested

against gp90 (top spot), viral p26 (middle spot) and recombinant
p26 (rec-p26) (bottom spot).

Intense spots at gp90 or p26 sites

indicate presence of EIAV specific antibodies.
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Fig. 4: SIB test analysis of equine sera with equivocal AGID reactions.
Reference EIA negative horse serum is tested in lane A and
reference positive EIA horse (Lady) serum is tested in lane D,
respectively.

Sera with equivocal AGID reactions (Flicker and

FLA 253) are tested in lanes B and C, respectively.
were

tested

against

recombinant p26 (r-26).

gp90,

HPLC

purified

p26

All sera

(v-p26)

and

CHAPTER FIVE

GENERAL DISCUSSION
This study was conducted to characterize variants of EIAV recovered
from infected Shetland ponies and variants generated in cell culture, and
to determine the nature of specific antibody responses during infection.
The course
descriptions

of EIA observed in this study was consistent with previous
(14,

18, 27).

Seven virus isolates were

plasma collected during febrile episodes.
A/1-4 were

recovered

from

In published reports isolates

designated as P3.3-1, P3.3-2, P3.3-3 and P3.3-4

for passage

level in ponies (P3), animal number (3, 4, 5), and febrile episode (1, 2,
etc.) (13,30).
Recurrent febrile

episodes were observed during chronic EIA and

viruses recovered from these
different.

episodes were

shown to be

serologically

The rate of emergence and the number of serologically distinct

variants in each animal was different.

The demonstration that isolates

recovered during febrile episodes 4-5 weeks apart were only neutralized
by

homologous

identified with
variation.

sera
MAbs

This study

and

that

confirmed

definite

antigenic

that EIAV

changes

undergoes

could

rapid

extends previous reports which have

be

antigenic

shown that

during persistent infection, EIAV undergoes rapid structural and antigenic
alterations in gp90 and gp45 which appear to result from point mutations
in the

env gene

(13,

22, 28, 29, 30,

31). In addition,

this

study

demonstrated that the rapid variation of EIAV observed in persistently
infected animals has an immunological basis as the neutralizing specificity
of selecting serum appeared to determine the serological divergence of
125
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the in vitro variant.
The generation of an in vitro variant of EIAV suggested that mutant
viruses that appear during virus replication require a selecting medium in
order to replace parental virus.

In the presence of neutralizing antibody,

the parental virus and the closely related mutant viruses are neutralized
while more divergent mutants continue to replicate.
neutralizing
pressure

antibodies

in

infected

cell

cultures

The presence of

provide

a

selection

that operates on virus variants generated by an independent

mechanism of genetic variation of the viral genome.

Non-neutralizing

antibodies may interfere with virus maturation by causing "patching and
capping" of cell membrane-bound viral glycoproteins.
virus

can

also

bud

into

cytoplasmic

neutralizing antibodies may be minimal.

vacuoles,

However, as the

the

effect

of

non

As most of the genetic variation

is likely to occur during reverse transcription of the viral genome, the
replication of virus in cells that are susceptible to lytic-infection will
increase the rate at which genome variation occurs.

In contrast, the

replication of virus in persistently infected cells is likely to limit the rate
of genome variation as the majority of the virus probably replicates from
proviruses

established

during

the

first

few

susceptible uninfected cells are still available.

rounds

of infection

when

Once maximum cell density

in culture is achieved and the pool of susceptible cells has been infected,
homologous superinfection which is required to maintain cycles of reverse
transcription may be prevented by mechanisms which would result in a
decrease in expression of viral receptor.

Such a process may proceed via

receptor interaction with shed viral envelope glycoproteins followed by
receptor-ligand

internalization,

formation

of

receptor-ligand

complexes
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between nascent cellular and viral envelope proteins or reduction in the
steady state synthesis of the receptor molecules.

A similar mechanism of

receptor down-regulation occurs in T cells persistently infected with HIV
where expression of the HIV receptor (CD4) on cell surface is decreased
through reduction of mRNA synthesis and the formation of complexes of
available CD4 with viral envelope products

(9).

The faster rate

of

emergence of antigenic variants in vivo may thus be explained by the
lytic infection of susceptible cells including monocytes and macrophages
accompanied by selection pressure operating at both the B- and T-cell
epitopes.
The ability of heterologous serum to partially neutralize the in vitro
virus variant suggested that either the specificity of the selecting serum
determines the serological divergence of the new virus or more than one
site

is

involved

mutually exclusive.

in

virus

neutralization.

These

possibilities

are

not

More than one site is involved in the neutralization

of many viruses including influenza virus and HIV and mutants that resist
neutralization by one MAb may retain their sensitivity to neutralization
by MAbs 'mapping at different epitopes (10, 35).

Results presented in this

study demonstrated that antigenic variation allows EIAV to infect host
cells in the presence of immune sera.
variants

in

vivo

may

eventually

be

The evolution of new virus
controlled

by

the

presence

of

immunological specificities that can accommodate a variety of antigenic
alterations. Knowledge of these immunological specificities and the viral
antigens that elicit them will be necessary for the design of effective
vaccines.
The

humoral

responses

to

EIAV

during persistent

infection were

128
monitored by AGID, Western blotting and virus neutralization.
IgG to gp90 was demonstrable within 2 weeks after infection.

Specific
The rate

of appearance of IgG to gp45 was slower than that observed for gp90 and
p26.

Although this early IgG had no virus neutralizing activity in vitro.

it is likely that in vivo, antibodies binding to these proteins can be
protective by complement or cellular dependent mechanisms.

Furthermore,

specific IgM responses which were not monitored in this study may have
important protective roles before the appearance of specific IgG.

Type-

specific neutralizing antibodies appeared within 2 months after infection.
These

results

are

in

agreement with previous

reports

indicating

that

neutralizing antibodies appeared 45-87 days after infection and peaked 3-5
months after infection (17).

The broad neutralizing activity of serum

collected late in the infection could have on the one hand resulted

from

sequential stimulation of the immune system with multiple virus variants
as may have been the case with ponies A and B.

On the other hand, the

specificity of neutralizing antibody may have broadened through repeated
stimulation of the immune system with one virus strain as might have
been the case with pony C.
Stimulation of the immune system with either sequential virus strains
or one virus strain has been shown to elicit broadly neutralizing antibod
ies in sheep infected with visna virus or in chimpanzees infected with a
strain of HIV, respectively (24, 25).

However, the facility with which the

lentiviruses alter their surface glycoproteins (3, 7, 8, 29, 30) suggests
that

during

"quasispecies"

persistent
(5)

infections

rather

than

the
a

immune

monotypic

system

is stimulated

strain

of

virus.

by
The

broadening of the humoral response may result from stimulation of the

immune system with a spectrum or "cock tail" of virus variants, which
may differ in their replication but not immunogenic potential.

The virus

populations that predominate in cell culture represent variants capable of
replicating extensively under the culture conditions.

This may not be the

variant that replicates predominantly in vivo where a variety of target
cells are likely to be involved.

The rate of appearance of specific IgG

and recurrences of acute EIA imply that conserved epitopes are not likely
targets

for

protective

immune

responses.

The

failure

of

antibodies

binding to these conserved epitopes to control virus replication suggest
that: the virus replicates in sites with low concentrations of antibodies;
or the virus is predominantly maturing into cytoplasmic vacuoles; or the
relevant antigens are not expressed on infected cells.
shedding

of

lentiviruses

envelope
may

antibody-dependent

proteins

direct

which

immune

cell-mediated

away from infected cells.

has

been

mechanism,
cytotoxicity

On the other hand,
recognized

e.g.,

cytotoxic

(ADCC)

and

for

other

T

cells,

complement

The course of EIA and the early appearance

of specific IgG which bind to homologous and heterologous virus isolates
but

display

type-specific

neutralizing

activity

suggests

that

protective

immune responses broaden as a result of stimulation with a spectrum of
viruses with modifications at specific B- and probably T- cell epitopes.
The delayed appearance of antibodies capable of neutralizing virus in
vitro suggests that other mechanisms may be important in the control of
viremia.

Leukocytes with direct cytolytic activity appear 14 to 18 days

after infection with EIAV (6) suggesting minor role in controlling viremia
which in this study peaked 2 to 3 weeks after infection.
not

IgG(T)

has

been

shown

to

mediate

antibody

Equine IgG but

dependent

cellular
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cytotoxicity (ADCC); however, leukocytes from infected horses failed to
lyse

cells

infected

with

EIAV

but

lysed

heterologous

target

cells

indicating a specific inability for these cells to eliminate EIAV infected
cells (6).

The absence of effective ADCC during infection with EIAV may

explain the inability of horses to control virus replication despite high
levels of binding antibodies.

On the other hand, it would be of interest

to find out whether horses who produce high levels of IgG(T) succumb to
recurrent episodes of acute EIA since this subclass of IgG inhibits both
ADCC and complement fixation (6, 21).
of

neutralizing

complement
systems,

the

antibody

with

or

can

be

without

transmembrane

Control of viremia in the absence

mediated

specific
protein

by

interferon,

antibody.

has

been

In
shown

classical pathway of complement and to bind C l (1, 4).

fever,

other
to

and

retrovirus

activate

the

The acute signs

of EIA i.e., fever and depression, are suggestive of increased macrophage
function

probably

complement

and

in

response

interleukin-1

to

opsonized

from

virions.

activated

Components

macrophages

may

of
be

responsible for fever, depression and the low levels of platelets seen in
acute EIA.
The variable course of EIA may be due to many factors including
host

susceptibility

and

major

histocompatibility

genes,

i.e.

equine

leukocyte antigens (ELA), virus strain and intercurrent disease processes.
In

this

study,

each

pony

receiving the same plasma.

had

a

different

course

of infection

after

It was difficult to explain the variability in

the course of EIA based on the kinetics of humoral response as no
difference was detected.

Other host factors are likely to be important.

It is likely that ponies with appropriate ELA haplotypes become optimally
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stimulated by the mosaic of "critical" B- and T-lymphocyte epitopes in
the parent virus population.

Such horses would remain afebrile after the

first episode i.e., pony C.

Conversely, ponies with inappropriate ELA

haplotypes would be incapable of recognizing all the "critical" epitopes in
the parent virus population.

Such ponies i.e., ponies A and B, would

allow virus mutants to leak through the narrow immune spectrum until a
sufficient spectrum of immunological memory is elicited.

At present it is

difficult to predict the immunological factors that are important in the
control of virus replication and cessation of recurrent febrile episodes.
is apparent
disease

that

humoral

progression

or

responses
virus

is

either

appear

spreading

from

too

late

to

cell-to-cell

It

arrest
causing

pathology regardless of the neutralizing specificity of antibodies.

The

influence of ELA haplotypes on the pathogenesis of EIA can be studied
with recipients sharing a single haplotype.

This can be achieved by

infecting genetically identical horses obtained through embiyo splitting.
The ability of lentiviruses to undergo antigenic variation presents a
formidable challenge to the development of effective immunogens.
genomes

of sequential

EIAV

nucleotide sequence (29, 30).

isolates

demonstrate

differences

The
in

their

Within the gp90 region, conserved, variable

and hypervariable regions have been identified; most of the amino acid
substitutions

in

the

glycosylation sites (30).

hypervariable

region

involved

potential

N-linked

Alterations of potential glycosylation sites may

explain the variation in glycopeptide maps previously observed in a set of
parallel third passage isolates (31).

The variation involving peptide and

glycosylation patterns in each virus isolate may alter antigenicity, thus
allowing each virus strain to circumvent specific immune factors elicited
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by

progenitor viruses.

In influenza

virus,

removal

of

a

potential

glycosylation site in H5N2 was associated with high virulence as a result
of unmasking

of a cleavage

site (16).

It is likely that

alteration of

glycosylation patterns of EIAV may alter host range, immunogenicity and
antigenicity.

Of interest in this regard

is the apparent

resistance of

wild-type EIAV to infect cultured equine fibroblasts.

The level at which

this

In

restriction

operates

is

currently not

known.

other

lentivirus

systems, restriction has been shown to operate at the level of host cell
recognition

(19, 20).

The

failure

of wild-type virus

to

replicate

in

cultured equine fibroblasts suggests that the wild-type virus predominantly
replicates

in

a

different

cell

type

in

vivo.

Different

glycosylation

patterns in wild-type virus may alter recognition by putative prototype
virus receptor

on FEK cells.

This can

be explained in

the following

hypothetical scenario: during infection of ponies with prototype virus only
spontaneous

mutants

with

altered

host

cell specificity are

infecting target cells associated with replication of EIAV.

capable

of

Conversely,

only those spontaneous host range mutants are capable of replicating in
FEK cells during virus reisolation from plasma.

In both directions, only

a very minor virus population of spontaneous mutants is initially present.
Accordingly, virulence of prototype virus increased with serial passage in
ponies (26) probably as a result of predominant virus population gradually
shifting from an "FEK-population" to an "in vivo population".

A reverse

shift in population may occur during virus reisolation in FEK cells which
takes at least 6 weeks of culture.

The ability of the prototype virus to

replicate in this manner suggests a hot-spot genetic defect that is absent
in wild-type virus.

Clearly a need to explore the in vivo target cells for
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EIAV

exists

and

previous

data

implicating

monocyte/macrophages

on

immunofluorescence data need to be extended with technology capable of
distinguishing between passive antigen expression (phagocytosis of viralantibody complexes) and authentic virus infection i.e. proviral DNA.

The

isolation of monocytes and lymphocytes from horses with chronic EIA and
their fusion with FEK cells can determine whether the restriction of
wild-type EIAV to replicate in this cells is at receptor recognition.
In EIA, after a number of clinical episodes, infected horses may die
or remain asymptomatic.

The eventual cessation of recurrent clinical EIA

is thought to have an immunological basis (2).

The neutralizing activity

of convalescent serum antibody increased with time and was highly cross
reactive late in the infection.
that

given

several

enough

virus

responses.

This observation leads to the suggestion

immunological

strains,

horses

would

stimulation,

e.g.,

immunization

develop

broadly

reactive

with

immune

However, the role of neutralizing antibody in the pathogenesis

of lentivirus infections is challenged by the frequent observation that the
level of neutralizing antibody does not appear to influence the course of
disease.

For example, in this study all the ponies died despite the

presence of neutralizing antibodies that were detectable as early as 2
months after infection.

Similarly, neutralizing antibodies are present in

the sera of both asymptomatic HIV seropositive persons and in AIDS
patients

suggesting that naturally developing neutralizing

little protection (33, 34).

antibody

offer

Moreover, immunization of chimpanzees with

vaccinia-HIV env recombinants did not avert challenge infection despite
the presence of specific antibody and T-cell responses (11).

Analysis of

the

seropositive

humoral

and

cellular

immune

responses

in

healthy
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individuals

(i.e., ponies who have

survived for long periods following

infection) might shed some light into the nature of long-term protective
immune mechanisms.

In addition, full knowledge of the interaction of

these lentiviruses with other intercurrent pathogens in the disease process
may aid in the design of disease management protocols.
that

herpes

viruses

and

lentiviruses

may possess

The recognition

transactivating

genes

raises the speculation of potentiation of viral gene expression during dual
infection with these viruses and a possible fatal outcome.
The diagnosis of viral infections by detection of specific antibody is
limited

to

measurable.

the

phase

of infection when

responses

are

The time between infection and detection of infection by

serology is variable

in most viral infections and represents

window

in disease control measures.

are

viruses

the

immunological

which

cause

a

critical

Of greatest concern in this regard

persistent

viremia

in

their

hosts

since

infected individuals can directly or indirectly disseminate virus for long
periods prior to diagnosis.

For this reason, technology that can directly

determine the presence of virus in an individual is most desirable.

In the

absence of such technology, continued search for simpler, inexpensive and
sensitive

serological

immunoblot

method

diagnosis of EIA.

tests

is

implied.

was

evaluated

for

In

this

study,

its

application

a
in

single-step
the

rapid

The SIB test relies on the binding of colloidal gold

conjugated with protein A to the Fc- portion of specific antibodies

that

react with antigens

sera

attached to a support matrix.

By reacting test

with both gp90 and p26, a level of sensitivity and specificity similar to
that of the approved diagnostic tests for EIA was achieved.
also

proved

more

efficient

in detection

of

EIAV

antigens

This test
in

the

135
supernatant fluids of persistently infected cell cultures.
In a limited study, a rabbit was immunized with lentil-lectin purified
glycoproteins of prototype EIAV.
in ELISA using purified virus.

Immune serum contained titers

103-6

The antibodies reacted with several virus

isolates including prototype EIAV.

Immunoblot analysis of this serum and

sera from rabbits immunized with whole or detergent disrupted prototype
EIAV

indicated

strong

activity

to

gp90

and

low

activity

to

gp45.

However, the anti-glycoprotein serum failed to neutralize homologous or
heterologous virus isolates.

In contrast, sera from

rabbits immunized

with whole or detergent

disrupted virus had high neutralizing activity

(Issel, unpublished results).

The failure of the rabbit serum to neutralize

virus suggested that soluble purified glycoproteins may not possess the
epitopes that are important for eliciting neutralizing antibodies.

These

results indicated that for the desired immune response to be achieved the
antigens

will

have

conformations.

In

to

be

presented

a pilot study,

disulfide-activating reagents

in

a

form

that

ensures

treatment of prototype

native

EIAV with

such as 2,2’-dithiobis-m-nitropyridine

did

not

lead to the formation of heterodimers of gp90 and gp45 (data not shown).
In other retroviruses, heterodimers of the outer envelope glycoprotein and
the

transmembrane

protein

have

been

shown

to

elicit

more

potent

protective immune responses than the individual proteins (12, 32).

For

viruses that cannot form such heterodimers, immunostimulating complexes
(ISCOMS) of glycosides with the glycoprotein inserted in a multimeric
form (23) would be a better form of antigen presentation.
The

demonstration

that

the

hydrophobic amino

terminus

of gp41

contains a fusogenic domain responsible for the fusion event following
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gpl20-CD4 binding and

that mutations in this region interfered with

membrane fusion (15) suggests a more significant role for this protein in
the infection process.

In other viruses, membrane fusion is a function of

the hydrophobic amino terminus of an integral membrane protein that
undergoes

maturation by

and paramyxoviruses.
envelope

and

proteolytic

cleavage,

e.g the orthomyxoviruses

It is likely that binding of antibodies to the outer

the

transmembrane

protein

m ediate

cooperative

neutralization which is more potent than that achieved by antibodies to
either

protein alone.

The time of appearance of neutralizing antibodies in

horses with EIA suggest that antibodies to gp90 and gp45 may cooperate
in virus neutralization.
may

facilitate

virolysis.
EIAV

antibody

Furthermore, the transmembrane location of gp45
dependent

complement

mediated

cytolysis

and

Information on the immunochemistry of the glycoproteins of
and their specific roles in the early events in virus replication

cycle

will

purification

be
of

necessary in
non-replicative

designing

strategies

immunogens

for

for production

control

of

EIA.

and
As

antigenic variation in this virus appears to be unlimited at the population
level,

a

need

to

determine

clusters

of

immunodominant

and

more

genetically stable variants from the panel of those generated in vivo and
in vitro is evident.

Trials with inactivated immunodominant virus variants

may open the way for the development and use of cock tails of subunit
vaccines that will be protective.
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